https://www.agenusbio.com/fr https://www.agenusbio.com/es https://www.agenusbio.com https://www.agenusbio.com/fr/partnerships https://www.agenusbio.com/es/partnerships https://www.agenusbio.com/partnerships https://www.agenusbio.com/fr/immunotherapy https://www.agenusbio.com/es/immunotherapy https://www.agenusbio.com/immunotherapy https://www.agenusbio.com/fr/pipeline https://www.agenusbio.com/es/pipeline https://www.agenusbio.com/pipeline https://www.agenusbio.com/fr/clinical-trials https://www.agenusbio.com/es/clinical-trials https://www.agenusbio.com/clinical-trials https://www.agenusbio.com/fr/publications https://www.agenusbio.com/es/publications https://www.agenusbio.com/publications https://www.agenusbio.com/fr/bot-bal https://www.agenusbio.com/es/bot-bal https://www.agenusbio.com/bot-bal https://www.agenusbio.com/fr/join-us https://www.agenusbio.com/es/join-us https://www.agenusbio.com/join-us https://www.agenusbio.com/fr/patients https://www.agenusbio.com/es/patients https://www.agenusbio.com/patients https://www.agenusbio.com/fr/corporate-presentation https://www.agenusbio.com/es/corporate-presentation https://www.agenusbio.com/corporate-presentation https://www.agenusbio.com/fr/team https://www.agenusbio.com/es/team https://www.agenusbio.com/team https://www.agenusbio.com/fr/our-history https://www.agenusbio.com/es/our-history https://www.agenusbio.com/our-history https://www.agenusbio.com/fr/in-the-news https://www.agenusbio.com/es/in-the-news https://www.agenusbio.com/in-the-news https://www.agenusbio.com/fr/contact-medical-affairs https://www.agenusbio.com/es/contact-medical-affairs https://www.agenusbio.com/contact-medical-affairs https://www.agenusbio.com/fr/privacy-policy https://www.agenusbio.com/es/privacy-policy https://www.agenusbio.com/privacy-policy https://www.agenusbio.com/fr/access-to-investigational-medicines-policy https://www.agenusbio.com/es/access-to-investigational-medicines-policy https://www.agenusbio.com/access-to-investigational-medicines-policy https://www.agenusbio.com/fr/the-original-immuno-oncology-innovator https://www.agenusbio.com/es/the-original-immuno-oncology-innovator https://www.agenusbio.com/the-original-immuno-oncology-innovator https://www.agenusbio.com/fr/frequently-asked-questions https://www.agenusbio.com/es/frequently-asked-questions https://www.agenusbio.com/frequently-asked-questions https://www.agenusbio.com/fr/terms https://www.agenusbio.com/es/terms https://www.agenusbio.com/terms https://www.agenusbio.com/fr/cookie-policy https://www.agenusbio.com/es/cookie-policy https://www.agenusbio.com/cookie-policy https://www.agenusbio.com/fr/opt-out-policy https://www.agenusbio.com/es/opt-out-policy https://www.agenusbio.com/opt-out-policy https://www.agenusbio.com/fr/community-guidelines https://www.agenusbio.com/es/community-guidelines https://www.agenusbio.com/community-guidelines https://www.agenusbio.com/fr/physician-resources https://www.agenusbio.com/es/physician-resources https://www.agenusbio.com/physician-resources https://www.agenusbio.com/fr/corporate-overview https://www.agenusbio.com/es/corporate-overview https://www.agenusbio.com/corporate-overview https://www.agenusbio.com/press/AgenTus-Therapeutics-to-Present-on-Novel-TCR-Platform-and-Progress-at-PEGS-Summit-in-Boston-MA-05-01-2018 https://www.agenusbio.com/fr/press/AgenTus-Therapeutics-to-Present-on-Novel-TCR-Platform-and-Progress-at-PEGS-Summit-in-Boston-MA-05-01-2018 https://www.agenusbio.com/es/press/AgenTus-Therapeutics-to-Present-on-Novel-TCR-Platform-and-Progress-at-PEGS-Summit-in-Boston-MA-05-01-2018 https://www.agenusbio.com/press/AgenTus-Therapeutics-to-Present-on-the-Anti-tumor-Activities-of-Two-Proprietary-T-Cell-Receptors-TCRs-at-CAR-TCR-Summit-in-Boston-MA-09-05-2018 https://www.agenusbio.com/fr/press/AgenTus-Therapeutics-to-Present-on-the-Anti-tumor-Activities-of-Two-Proprietary-T-Cell-Receptors-TCRs-at-CAR-TCR-Summit-in-Boston-MA-09-05-2018 https://www.agenusbio.com/es/press/AgenTus-Therapeutics-to-Present-on-the-Anti-tumor-Activities-of-Two-Proprietary-T-Cell-Receptors-TCRs-at-CAR-TCR-Summit-in-Boston-MA-09-05-2018 https://www.agenusbio.com/press/Agenus-Acquires-Celexion-Assets-and-Expands-Its-Antibody-Discovery-Platform-04-08-2015 https://www.agenusbio.com/fr/press/Agenus-Acquires-Celexion-Assets-and-Expands-Its-Antibody-Discovery-Platform-04-08-2015 https://www.agenusbio.com/es/press/Agenus-Acquires-Celexion-Assets-and-Expands-Its-Antibody-Discovery-Platform-04-08-2015 https://www.agenusbio.com/press/Agenus-Acquires-Novel-Antibodies-to-Immuno-oncology-Target-CEACAM1-07-20-2015 https://www.agenusbio.com/fr/press/Agenus-Acquires-Novel-Antibodies-to-Immuno-oncology-Target-CEACAM1-07-20-2015 https://www.agenusbio.com/es/press/Agenus-Acquires-Novel-Antibodies-to-Immuno-oncology-Target-CEACAM1-07-20-2015 https://www.agenusbio.com/press/Agenus-Acquires-PhosImmune-with-a-Novel-Class-of-Cancer-Neoantigens-12-23-2015 https://www.agenusbio.com/fr/press/Agenus-Acquires-PhosImmune-with-a-Novel-Class-of-Cancer-Neoantigens-12-23-2015 https://www.agenusbio.com/es/press/Agenus-Acquires-PhosImmune-with-a-Novel-Class-of-Cancer-Neoantigens-12-23-2015 https://www.agenusbio.com/press/Agenus-Advances-Portfolio-with-6-Clinical-Collaborations-05-31-2022 https://www.agenusbio.com/fr/press/Agenus-Advances-Portfolio-with-6-Clinical-Collaborations-05-31-2022 https://www.agenusbio.com/es/press/Agenus-Advances-Portfolio-with-6-Clinical-Collaborations-05-31-2022 https://www.agenusbio.com/press/Agenus-Announces-Agenus-Insights-Virtual-RD-Miniseries-02-09-2021 https://www.agenusbio.com/fr/press/Agenus-Announces-Agenus-Insights-Virtual-RD-Miniseries-02-09-2021 https://www.agenusbio.com/es/press/Agenus-Announces-Agenus-Insights-Virtual-RD-Miniseries-02-09-2021 https://www.agenusbio.com/press/Agenus-Announces-Appointment-of-Tom-Harrison-to-Board-of-Directors https://www.agenusbio.com/fr/press/Agenus-Announces-Appointment-of-Tom-Harrison-to-Board-of-Directors https://www.agenusbio.com/es/press/Agenus-Announces-Appointment-of-Tom-Harrison-to-Board-of-Directors https://www.agenusbio.com/press/Agenus-Announces-Botensilimab-and-Balstilimab-Presentations-at-ASCO-2025 https://www.agenusbio.com/fr/press/Agenus-Announces-Botensilimab-and-Balstilimab-Presentations-at-ASCO-2025 https://www.agenusbio.com/es/press/Agenus-Announces-Botensilimab-and-Balstilimab-Presentations-at-ASCO-2025 https://www.agenusbio.com/press/Agenus-Announces-Clearance-of-Investigational-New-Drug-Applications-by-the-FDA-for-anti-CTLA-4-and-anti-GITR-Antibodies-01-21-2016 https://www.agenusbio.com/fr/press/Agenus-Announces-Clearance-of-Investigational-New-Drug-Applications-by-the-FDA-for-anti-CTLA-4-and-anti-GITR-Antibodies-01-21-2016 https://www.agenusbio.com/es/press/Agenus-Announces-Clearance-of-Investigational-New-Drug-Applications-by-the-FDA-for-anti-CTLA-4-and-anti-GITR-Antibodies-01-21-2016 https://www.agenusbio.com/press/Agenus-Announces-Clinical-Appointments-03-21-2019 https://www.agenusbio.com/fr/press/Agenus-Announces-Clinical-Appointments-03-21-2019 https://www.agenusbio.com/es/press/Agenus-Announces-Clinical-Appointments-03-21-2019 https://www.agenusbio.com/press/Agenus-Announces-Closing-of-141M-Strategic-Collaboration-with-Zydus-Lifesciences-to-Advance-BOTBAL-and-Strengthen-U-S--Manufacturing-Readiness-8b0ce https://www.agenusbio.com/fr/press/Agenus-Announces-Closing-of-141M-Strategic-Collaboration-with-Zydus-Lifesciences-to-Advance-BOTBAL-and-Strengthen-U-S--Manufacturing-Readiness-8b0ce https://www.agenusbio.com/es/press/Agenus-Announces-Closing-of-141M-Strategic-Collaboration-with-Zydus-Lifesciences-to-Advance-BOTBAL-and-Strengthen-U-S--Manufacturing-Readiness-8b0ce https://www.agenusbio.com/press/Agenus-Announces-Closing-of-Public-Offering-and-Exercise-in-Full-of-Underwriters-Option-to-Purchase-Additional-Shares-of-Common-Stock-05-27-2015 https://www.agenusbio.com/fr/press/Agenus-Announces-Closing-of-Public-Offering-and-Exercise-in-Full-of-Underwriters-Option-to-Purchase-Additional-Shares-of-Common-Stock-05-27-2015 https://www.agenusbio.com/es/press/Agenus-Announces-Closing-of-Public-Offering-and-Exercise-in-Full-of-Underwriters-Option-to-Purchase-Additional-Shares-of-Common-Stock-05-27-2015 https://www.agenusbio.com/press/Agenus-Announces-Closing-of-Public-Offering-and-Exercise-of-Over-Allotment-Option-02-10-2014 https://www.agenusbio.com/fr/press/Agenus-Announces-Closing-of-Public-Offering-and-Exercise-of-Over-Allotment-Option-02-10-2014 https://www.agenusbio.com/es/press/Agenus-Announces-Closing-of-Public-Offering-and-Exercise-of-Over-Allotment-Option-02-10-2014 https://www.agenusbio.com/press/Agenus-Announces-Collaboration-and-License-Agreement-with-Merck-for-Novel-Checkpoint-Antibody-Based-Cancer-Immunotherapies-04-28-2014 https://www.agenusbio.com/fr/press/Agenus-Announces-Collaboration-and-License-Agreement-with-Merck-for-Novel-Checkpoint-Antibody-Based-Cancer-Immunotherapies-04-28-2014 https://www.agenusbio.com/es/press/Agenus-Announces-Collaboration-and-License-Agreement-with-Merck-for-Novel-Checkpoint-Antibody-Based-Cancer-Immunotherapies-04-28-2014 https://www.agenusbio.com/press/Agenus-Announces-Combination-Clinical-Trials-of-its-Anti-CTLA4-AGEN1884-Anti-PD1-AGEN2034-01-22-2018 https://www.agenusbio.com/fr/press/Agenus-Announces-Combination-Clinical-Trials-of-its-Anti-CTLA4-AGEN1884-Anti-PD1-AGEN2034-01-22-2018 https://www.agenusbio.com/es/press/Agenus-Announces-Combination-Clinical-Trials-of-its-Anti-CTLA4-AGEN1884-Anti-PD1-AGEN2034-01-22-2018 https://www.agenusbio.com/press/Agenus-Announces-Commencement-of-Phase-12-Clinical-Trial-of-anti-GITR-Checkpoint-Antibody-INCAGN1876-in-Patients-with-Solid-Tumors-06-22-2016 https://www.agenusbio.com/fr/press/Agenus-Announces-Commencement-of-Phase-12-Clinical-Trial-of-anti-GITR-Checkpoint-Antibody-INCAGN1876-in-Patients-with-Solid-Tumors-06-22-2016 https://www.agenusbio.com/es/press/Agenus-Announces-Commencement-of-Phase-12-Clinical-Trial-of-anti-GITR-Checkpoint-Antibody-INCAGN1876-in-Patients-with-Solid-Tumors-06-22-2016 https://www.agenusbio.com/press/Agenus-Announces-Commencement-of-Phase-12-Clinical-Trial-of-anti-OX40-Checkpoint-Antibody-INCAGN1949-in-Patients-with-Solid-Tumors-11-30-2016 https://www.agenusbio.com/fr/press/Agenus-Announces-Commencement-of-Phase-12-Clinical-Trial-of-anti-OX40-Checkpoint-Antibody-INCAGN1949-in-Patients-with-Solid-Tumors-11-30-2016 https://www.agenusbio.com/es/press/Agenus-Announces-Commencement-of-Phase-12-Clinical-Trial-of-anti-OX40-Checkpoint-Antibody-INCAGN1949-in-Patients-with-Solid-Tumors-11-30-2016 https://www.agenusbio.com/press/Agenus-Announces-Dividend-of-5-Million-Shares-of-MiNK-Therapeutics-03-30-2023 https://www.agenusbio.com/fr/press/Agenus-Announces-Dividend-of-5-Million-Shares-of-MiNK-Therapeutics-03-30-2023 https://www.agenusbio.com/es/press/Agenus-Announces-Dividend-of-5-Million-Shares-of-MiNK-Therapeutics-03-30-2023 https://www.agenusbio.com/press/Agenus-Announces-ESMO-Oral-Presentation-of-Two-Clinical-Trials-of-Balstilimab-Alone-and-in-Combination-with-Zalifrelimab-in-Recurrent-or-Metastatic-Cervical-Cancer-08-26-2020 https://www.agenusbio.com/fr/press/Agenus-Announces-ESMO-Oral-Presentation-of-Two-Clinical-Trials-of-Balstilimab-Alone-and-in-Combination-with-Zalifrelimab-in-Recurrent-or-Metastatic-Cervical-Cancer-08-26-2020 https://www.agenusbio.com/es/press/Agenus-Announces-ESMO-Oral-Presentation-of-Two-Clinical-Trials-of-Balstilimab-Alone-and-in-Combination-with-Zalifrelimab-in-Recurrent-or-Metastatic-Cervical-Cancer-08-26-2020 https://www.agenusbio.com/press/Agenus-Announces-End-of-Phase-2-Meeting-Outcomes-and-Topline-Interim-Phase-2-Data-for-BOTBAL-in-MSS-Colorectal-Cancer https://www.agenusbio.com/fr/press/Agenus-Announces-End-of-Phase-2-Meeting-Outcomes-and-Topline-Interim-Phase-2-Data-for-BOTBAL-in-MSS-Colorectal-Cancer https://www.agenusbio.com/es/press/Agenus-Announces-End-of-Phase-2-Meeting-Outcomes-and-Topline-Interim-Phase-2-Data-for-BOTBAL-in-MSS-Colorectal-Cancer https://www.agenusbio.com/press/Agenus-Announces-First-Patient-Dosed-in-Phase-1-Study-of-AGEN1571-anti-ILT2-in-Advanced-Solid-Tumors-08-01-2022 https://www.agenusbio.com/fr/press/Agenus-Announces-First-Patient-Dosed-in-Phase-1-Study-of-AGEN1571-anti-ILT2-in-Advanced-Solid-Tumors-08-01-2022 https://www.agenusbio.com/es/press/Agenus-Announces-First-Patient-Dosed-in-Phase-1-Study-of-AGEN1571-anti-ILT2-in-Advanced-Solid-Tumors-08-01-2022 https://www.agenusbio.com/press/Agenus-Announces-Five-Presentations-at-ASCO-GI-Highlighting-BOTBAL-Activity-Across-Colorectal-and-Gastric-Cancers https://www.agenusbio.com/fr/press/Agenus-Announces-Five-Presentations-at-ASCO-GI-Highlighting-BOTBAL-Activity-Across-Colorectal-and-Gastric-Cancers https://www.agenusbio.com/es/press/Agenus-Announces-Five-Presentations-at-ASCO-GI-Highlighting-BOTBAL-Activity-Across-Colorectal-and-Gastric-Cancers https://www.agenusbio.com/press/Agenus-Announces-Initiation-of-Enrollment-in-NCI-Sponsored-Randomized-Trial-of-Prophage-G-200-Vaccine-with-Avastin-in-Treatment-of-Brain-Tumors-05-22-2013 https://www.agenusbio.com/fr/press/Agenus-Announces-Initiation-of-Enrollment-in-NCI-Sponsored-Randomized-Trial-of-Prophage-G-200-Vaccine-with-Avastin-in-Treatment-of-Brain-Tumors-05-22-2013 https://www.agenusbio.com/es/press/Agenus-Announces-Initiation-of-Enrollment-in-NCI-Sponsored-Randomized-Trial-of-Prophage-G-200-Vaccine-with-Avastin-in-Treatment-of-Brain-Tumors-05-22-2013 https://www.agenusbio.com/press/Agenus-Announces-Investor-Day-on-February-20-2020-02-06-2020 https://www.agenusbio.com/fr/press/Agenus-Announces-Investor-Day-on-February-20-2020-02-06-2020 https://www.agenusbio.com/es/press/Agenus-Announces-Investor-Day-on-February-20-2020-02-06-2020 https://www.agenusbio.com/press/Agenus-Announces-Key-Leadership-to-Advance-Combination-Trials-For-Planned-BLA-Filings-01-03-2018 https://www.agenusbio.com/fr/press/Agenus-Announces-Key-Leadership-to-Advance-Combination-Trials-For-Planned-BLA-Filings-01-03-2018 https://www.agenusbio.com/es/press/Agenus-Announces-Key-Leadership-to-Advance-Combination-Trials-For-Planned-BLA-Filings-01-03-2018 https://www.agenusbio.com/press/Agenus-Announces-Late-Breaking-Oral-Presentation-at-ESMO-GI-and-Strategies-to-Advance-Botensilimab-05-24-2022 https://www.agenusbio.com/fr/press/Agenus-Announces-Late-Breaking-Oral-Presentation-at-ESMO-GI-and-Strategies-to-Advance-Botensilimab-05-24-2022 https://www.agenusbio.com/es/press/Agenus-Announces-Late-Breaking-Oral-Presentation-at-ESMO-GI-and-Strategies-to-Advance-Botensilimab-05-24-2022 https://www.agenusbio.com/press/Agenus-Announces-Lead-Product-Candidate-Selection-in-its-Collaboration-with-Merck-06-09-2016 https://www.agenusbio.com/fr/press/Agenus-Announces-Lead-Product-Candidate-Selection-in-its-Collaboration-with-Merck-06-09-2016 https://www.agenusbio.com/es/press/Agenus-Announces-Lead-Product-Candidate-Selection-in-its-Collaboration-with-Merck-06-09-2016 https://www.agenusbio.com/press/Agenus-Announces-New-Data-from-Expanded-MSS-Metastatic-Colorectal-Cancer-Cohort-to-be-Presented-at-ESMO-GI-2025 https://www.agenusbio.com/fr/press/Agenus-Announces-New-Data-from-Expanded-MSS-Metastatic-Colorectal-Cancer-Cohort-to-be-Presented-at-ESMO-GI-2025 https://www.agenusbio.com/es/press/Agenus-Announces-New-Data-from-Expanded-MSS-Metastatic-Colorectal-Cancer-Cohort-to-be-Presented-at-ESMO-GI-2025 https://www.agenusbio.com/press/Agenus-Announces-New-Responses-for-AGEN1181-02-09-2021 https://www.agenusbio.com/fr/press/Agenus-Announces-New-Responses-for-AGEN1181-02-09-2021 https://www.agenusbio.com/es/press/Agenus-Announces-New-Responses-for-AGEN1181-02-09-2021 https://www.agenusbio.com/press/Agenus-Announces-Oral-Presentation-at-ASCO-Highlighting-Improved-Survival-with-Prophage-Immunotherapy-in-Brain-Cancer-Compared-to-Historical-Controls-05-14-2015 https://www.agenusbio.com/fr/press/Agenus-Announces-Oral-Presentation-at-ASCO-Highlighting-Improved-Survival-with-Prophage-Immunotherapy-in-Brain-Cancer-Compared-to-Historical-Controls-05-14-2015 https://www.agenusbio.com/es/press/Agenus-Announces-Oral-Presentation-at-ASCO-Highlighting-Improved-Survival-with-Prophage-Immunotherapy-in-Brain-Cancer-Compared-to-Historical-Controls-05-14-2015 https://www.agenusbio.com/press/Agenus-Announces-Phase-2-Checkpoint-inhibitor-Combination-Trial-with-Prophage-Cancer-Vaccine-for-Melanoma-01-14-2014 https://www.agenusbio.com/fr/press/Agenus-Announces-Phase-2-Checkpoint-inhibitor-Combination-Trial-with-Prophage-Cancer-Vaccine-for-Melanoma-01-14-2014 https://www.agenusbio.com/es/press/Agenus-Announces-Phase-2-Checkpoint-inhibitor-Combination-Trial-with-Prophage-Cancer-Vaccine-for-Melanoma-01-14-2014 https://www.agenusbio.com/press/Agenus-Announces-Positive-Interim-Data-from-Balstilimab-and-Zalifrelimab-Clinical-Trials-in-Second-Line-Cervical-Cancer-02-20-2020 https://www.agenusbio.com/fr/press/Agenus-Announces-Positive-Interim-Data-from-Balstilimab-and-Zalifrelimab-Clinical-Trials-in-Second-Line-Cervical-Cancer-02-20-2020 https://www.agenusbio.com/es/press/Agenus-Announces-Positive-Interim-Data-from-Balstilimab-and-Zalifrelimab-Clinical-Trials-in-Second-Line-Cervical-Cancer-02-20-2020 https://www.agenusbio.com/press/Agenus-Announces-Positive-Preliminary-Results-of-iNKT-Cell-Therapy-Trial-in-COVID-19-02-04-2021 https://www.agenusbio.com/fr/press/Agenus-Announces-Positive-Preliminary-Results-of-iNKT-Cell-Therapy-Trial-in-COVID-19-02-04-2021 https://www.agenusbio.com/es/press/Agenus-Announces-Positive-Preliminary-Results-of-iNKT-Cell-Therapy-Trial-in-COVID-19-02-04-2021 https://www.agenusbio.com/press/Agenus-Announces-Preclinical-Data-on-BMS-986442-AGEN1777-at-AACR-2024 https://www.agenusbio.com/fr/press/Agenus-Announces-Preclinical-Data-on-BMS-986442-AGEN1777-at-AACR-2024 https://www.agenusbio.com/es/press/Agenus-Announces-Preclinical-Data-on-BMS-986442-AGEN1777-at-AACR-2024 https://www.agenusbio.com/press/Agenus-Announces-Pricing-of-Its-Public-Offering-of-Common-Stock-05-21-2015 https://www.agenusbio.com/fr/press/Agenus-Announces-Pricing-of-Its-Public-Offering-of-Common-Stock-05-21-2015 https://www.agenusbio.com/es/press/Agenus-Announces-Pricing-of-Its-Public-Offering-of-Common-Stock-05-21-2015 https://www.agenusbio.com/press/Agenus-Announces-Proposed-Public-Offering-of-Common-Stock-05-21-2015 https://www.agenusbio.com/fr/press/Agenus-Announces-Proposed-Public-Offering-of-Common-Stock-05-21-2015 https://www.agenusbio.com/es/press/Agenus-Announces-Proposed-Public-Offering-of-Common-Stock-05-21-2015 https://www.agenusbio.com/press/Agenus-Announces-Publication-in-the-Journal-of-Clinical-Oncology-Highlighting-Data-from-Botensilimab-Plus-Balstilimab-in-RelapsedRefractory-Metastatic-Sarcomas https://www.agenusbio.com/fr/press/Agenus-Announces-Publication-in-the-Journal-of-Clinical-Oncology-Highlighting-Data-from-Botensilimab-Plus-Balstilimab-in-RelapsedRefractory-Metastatic-Sarcomas https://www.agenusbio.com/es/press/Agenus-Announces-Publication-in-the-Journal-of-Clinical-Oncology-Highlighting-Data-from-Botensilimab-Plus-Balstilimab-in-RelapsedRefractory-Metastatic-Sarcomas https://www.agenusbio.com/press/Agenus-Announces-Reverse-Stock-Split-of-Common-Stock https://www.agenusbio.com/fr/press/Agenus-Announces-Reverse-Stock-Split-of-Common-Stock https://www.agenusbio.com/es/press/Agenus-Announces-Reverse-Stock-Split-of-Common-Stock https://www.agenusbio.com/press/Agenus-Announces-Second-Quarter-2025-Financial-Results-and-Virtual-Meeting-to-Discuss-Strategic-Progress-43c1d https://www.agenusbio.com/fr/press/Agenus-Announces-Second-Quarter-2025-Financial-Results-and-Virtual-Meeting-to-Discuss-Strategic-Progress-43c1d https://www.agenusbio.com/es/press/Agenus-Announces-Second-Quarter-2025-Financial-Results-and-Virtual-Meeting-to-Discuss-Strategic-Progress-43c1d https://www.agenusbio.com/press/Agenus-Announces-Strategic-Realignment-to-Focus-on-Core-Programs-and-Significantly-Reduce-Costs https://www.agenusbio.com/fr/press/Agenus-Announces-Strategic-Realignment-to-Focus-on-Core-Programs-and-Significantly-Reduce-Costs https://www.agenusbio.com/es/press/Agenus-Announces-Strategic-Realignment-to-Focus-on-Core-Programs-and-Significantly-Reduce-Costs https://www.agenusbio.com/press/Agenus-Announces-Updated-Phase-1-Data-and-Progress-on-BOTBAL-Development-in-Metastatic-MSS-Colorectal-Cancer https://www.agenusbio.com/fr/press/Agenus-Announces-Updated-Phase-1-Data-and-Progress-on-BOTBAL-Development-in-Metastatic-MSS-Colorectal-Cancer https://www.agenusbio.com/es/press/Agenus-Announces-Updated-Phase-1-Data-and-Progress-on-BOTBAL-Development-in-Metastatic-MSS-Colorectal-Cancer https://www.agenusbio.com/press/Agenus-Announces-Virtual-Annual-Shareholders-Meeting https://www.agenusbio.com/fr/press/Agenus-Announces-Virtual-Annual-Shareholders-Meeting https://www.agenusbio.com/es/press/Agenus-Announces-Virtual-Annual-Shareholders-Meeting https://www.agenusbio.com/press/Agenus-Announces-Virtual-Annual-Shareholders-Meeting-06-15-2021 https://www.agenusbio.com/fr/press/Agenus-Announces-Virtual-Annual-Shareholders-Meeting-06-15-2021 https://www.agenusbio.com/es/press/Agenus-Announces-Virtual-Annual-Shareholders-Meeting-06-15-2021 https://www.agenusbio.com/press/Agenus-Appoints-Don-Vidic-as-Vice-President-and-Head-of-Commercial-07-18-2019 https://www.agenusbio.com/fr/press/Agenus-Appoints-Don-Vidic-as-Vice-President-and-Head-of-Commercial-07-18-2019 https://www.agenusbio.com/es/press/Agenus-Appoints-Don-Vidic-as-Vice-President-and-Head-of-Commercial-07-18-2019 https://www.agenusbio.com/press/Agenus-Appoints-Dr--Jos-Iglesias-as-Chief-Medical-Affairs-Officer-to-Guide-Global-Medical-Affairs-and-Early-Access-Programs-Including-Frances-AAC-bc1e8 https://www.agenusbio.com/fr/press/Agenus-Appoints-Dr--Jos-Iglesias-as-Chief-Medical-Affairs-Officer-to-Guide-Global-Medical-Affairs-and-Early-Access-Programs-Including-Frances-AAC-bc1e8 https://www.agenusbio.com/es/press/Agenus-Appoints-Dr--Jos-Iglesias-as-Chief-Medical-Affairs-Officer-to-Guide-Global-Medical-Affairs-and-Early-Access-Programs-Including-Frances-AAC-bc1e8 https://www.agenusbio.com/press/Agenus-Appoints-Regulatory-and-Clinical-Heads-07-16-2018 https://www.agenusbio.com/fr/press/Agenus-Appoints-Regulatory-and-Clinical-Heads-07-16-2018 https://www.agenusbio.com/es/press/Agenus-Appoints-Regulatory-and-Clinical-Heads-07-16-2018 https://www.agenusbio.com/press/Agenus-Appoints-Ulf-Wiinberg-to-Board-of-Directors-05-19-2016 https://www.agenusbio.com/fr/press/Agenus-Appoints-Ulf-Wiinberg-to-Board-of-Directors-05-19-2016 https://www.agenusbio.com/es/press/Agenus-Appoints-Ulf-Wiinberg-to-Board-of-Directors-05-19-2016 https://www.agenusbio.com/press/Agenus-Awarded-Grant-to-Enable-QS-21-Innovations-01-03-2019 https://www.agenusbio.com/fr/press/Agenus-Awarded-Grant-to-Enable-QS-21-Innovations-01-03-2019 https://www.agenusbio.com/es/press/Agenus-Awarded-Grant-to-Enable-QS-21-Innovations-01-03-2019 https://www.agenusbio.com/press/Agenus-BOTBAL-Achieves-42-Two-Year-Survival-in-Refractory-MSS-CRC-Advances-Toward-Registration-with-FDA-Alignment-on-Phase-3-44e96 https://www.agenusbio.com/fr/press/Agenus-BOTBAL-Achieves-42-Two-Year-Survival-in-Refractory-MSS-CRC-Advances-Toward-Registration-with-FDA-Alignment-on-Phase-3-44e96 https://www.agenusbio.com/es/press/Agenus-BOTBAL-Achieves-42-Two-Year-Survival-in-Refractory-MSS-CRC-Advances-Toward-Registration-with-FDA-Alignment-on-Phase-3-44e96 https://www.agenusbio.com/press/Agenus-BOTBAL-Data-in-Pretreated-Liver-Cancer-Presented-at-AACR-2025 https://www.agenusbio.com/fr/press/Agenus-BOTBAL-Data-in-Pretreated-Liver-Cancer-Presented-at-AACR-2025 https://www.agenusbio.com/es/press/Agenus-BOTBAL-Data-in-Pretreated-Liver-Cancer-Presented-at-AACR-2025 https://www.agenusbio.com/press/Agenus-BOTBAL-Neoadjuvant-Pan-Cancer-Data-from-the-NEOASIS-Study-Presented-in-an-Oral-Session-at-AACR https://www.agenusbio.com/fr/press/Agenus-BOTBAL-Neoadjuvant-Pan-Cancer-Data-from-the-NEOASIS-Study-Presented-in-an-Oral-Session-at-AACR https://www.agenusbio.com/es/press/Agenus-BOTBAL-Neoadjuvant-Pan-Cancer-Data-from-the-NEOASIS-Study-Presented-in-an-Oral-Session-at-AACR https://www.agenusbio.com/press/Agenus-BOTBAL-Selected-for-Two-Presentations-at-Upcoming-AACR-IO-Annual-Meeting https://www.agenusbio.com/fr/press/Agenus-BOTBAL-Selected-for-Two-Presentations-at-Upcoming-AACR-IO-Annual-Meeting https://www.agenusbio.com/es/press/Agenus-BOTBAL-Selected-for-Two-Presentations-at-Upcoming-AACR-IO-Annual-Meeting https://www.agenusbio.com/press/Agenus-Begins-Dosing-with-Next-Gen-Anti-CTLA-4-Antibody-04-02-2019 https://www.agenusbio.com/fr/press/Agenus-Begins-Dosing-with-Next-Gen-Anti-CTLA-4-Antibody-04-02-2019 https://www.agenusbio.com/es/press/Agenus-Begins-Dosing-with-Next-Gen-Anti-CTLA-4-Antibody-04-02-2019 https://www.agenusbio.com/press/Agenus-Botensilimab-Balstilimab-Data-Update-in-Sarcomas-Selected-for-Oral-Presentation-at-ESMO-2023 https://www.agenusbio.com/fr/press/Agenus-Botensilimab-Balstilimab-Data-Update-in-Sarcomas-Selected-for-Oral-Presentation-at-ESMO-2023 https://www.agenusbio.com/es/press/Agenus-Botensilimab-Balstilimab-Data-Update-in-Sarcomas-Selected-for-Oral-Presentation-at-ESMO-2023 https://www.agenusbio.com/press/Agenus-Botensilimab-in-Combination-with-Balstilimab-Shows-33-Durable-Responses-in-Ovarian-Cancer-03-27-2023 https://www.agenusbio.com/fr/press/Agenus-Botensilimab-in-Combination-with-Balstilimab-Shows-33-Durable-Responses-in-Ovarian-Cancer-03-27-2023 https://www.agenusbio.com/es/press/Agenus-Botensilimab-in-Combination-with-Balstilimab-Shows-33-Durable-Responses-in-Ovarian-Cancer-03-27-2023 https://www.agenusbio.com/press/Agenus-Brain-Cancer-Vaccine-Shows-Extended-Survival-in-Phase-2-Final-Data-Analysis-07-01-2014 https://www.agenusbio.com/fr/press/Agenus-Brain-Cancer-Vaccine-Shows-Extended-Survival-in-Phase-2-Final-Data-Analysis-07-01-2014 https://www.agenusbio.com/es/press/Agenus-Brain-Cancer-Vaccine-Shows-Extended-Survival-in-Phase-2-Final-Data-Analysis-07-01-2014 https://www.agenusbio.com/press/Agenus-CD137-Agonist-AGEN2373-Advances-in-the-Clinic-Triggering-Milestone-Payment-from-Gilead-04-05-2022 https://www.agenusbio.com/fr/press/Agenus-CD137-Agonist-AGEN2373-Advances-in-the-Clinic-Triggering-Milestone-Payment-from-Gilead-04-05-2022 https://www.agenusbio.com/es/press/Agenus-CD137-Agonist-AGEN2373-Advances-in-the-Clinic-Triggering-Milestone-Payment-from-Gilead-04-05-2022 https://www.agenusbio.com/press/Agenus-Cancels-Conference-Call-to-Discuss-the-Companys-Minority-Cash-Holdings-at-SVB-in-Light-of-Governments-SVB-Deposit-Access-Announcement-03-12-2023 https://www.agenusbio.com/fr/press/Agenus-Cancels-Conference-Call-to-Discuss-the-Companys-Minority-Cash-Holdings-at-SVB-in-Light-of-Governments-SVB-Deposit-Access-Announcement-03-12-2023 https://www.agenusbio.com/es/press/Agenus-Cancels-Conference-Call-to-Discuss-the-Companys-Minority-Cash-Holdings-at-SVB-in-Light-of-Governments-SVB-Deposit-Access-Announcement-03-12-2023 https://www.agenusbio.com/press/Agenus-Cell-Therapy-and-Checkpoint-Antibody-Combinations-Show-Curative-Preclinical-Efficacy-at-AACR-2020-06-22-2020 https://www.agenusbio.com/fr/press/Agenus-Cell-Therapy-and-Checkpoint-Antibody-Combinations-Show-Curative-Preclinical-Efficacy-at-AACR-2020-06-22-2020 https://www.agenusbio.com/es/press/Agenus-Cell-Therapy-and-Checkpoint-Antibody-Combinations-Show-Curative-Preclinical-Efficacy-at-AACR-2020-06-22-2020 https://www.agenusbio.com/press/Agenus-Closes-15-Million-Partial-Royalty-Monetization-With-XOMA-09-21-2018 https://www.agenusbio.com/fr/press/Agenus-Closes-15-Million-Partial-Royalty-Monetization-With-XOMA-09-21-2018 https://www.agenusbio.com/es/press/Agenus-Closes-15-Million-Partial-Royalty-Monetization-With-XOMA-09-21-2018 https://www.agenusbio.com/press/Agenus-Closes-150-Million-Immuno-Oncology-Transaction-with-Gilead-01-24-2019 https://www.agenusbio.com/fr/press/Agenus-Closes-150-Million-Immuno-Oncology-Transaction-with-Gilead-01-24-2019 https://www.agenusbio.com/es/press/Agenus-Closes-150-Million-Immuno-Oncology-Transaction-with-Gilead-01-24-2019 https://www.agenusbio.com/press/Agenus-Closes-200M-Upfront-BMS-Collaboration-and-Announces-FDA-Acceptance-of-IND-for-Partnered-Anti-TIGIT-Bispecific-Antibody-AGEN1777-07-06-2021 https://www.agenusbio.com/fr/press/Agenus-Closes-200M-Upfront-BMS-Collaboration-and-Announces-FDA-Acceptance-of-IND-for-Partnered-Anti-TIGIT-Bispecific-Antibody-AGEN1777-07-06-2021 https://www.agenusbio.com/es/press/Agenus-Closes-200M-Upfront-BMS-Collaboration-and-Announces-FDA-Acceptance-of-IND-for-Partnered-Anti-TIGIT-Bispecific-Antibody-AGEN1777-07-06-2021 https://www.agenusbio.com/press/Agenus-Commences-Combination-Trial-of-its-Next-Gen-CTLA-4-with-its-PD-1-Antibody-12-19-2019 https://www.agenusbio.com/fr/press/Agenus-Commences-Combination-Trial-of-its-Next-Gen-CTLA-4-with-its-PD-1-Antibody-12-19-2019 https://www.agenusbio.com/es/press/Agenus-Commences-Combination-Trial-of-its-Next-Gen-CTLA-4-with-its-PD-1-Antibody-12-19-2019 https://www.agenusbio.com/press/Agenus-Commences-Phase-1-Clinical-Trial-of-its-CTLA-4-Checkpoint-Antibody-to-Treat-Solid-Tumors-04-27-2016 https://www.agenusbio.com/fr/press/Agenus-Commences-Phase-1-Clinical-Trial-of-its-CTLA-4-Checkpoint-Antibody-to-Treat-Solid-Tumors-04-27-2016 https://www.agenusbio.com/es/press/Agenus-Commences-Phase-1-Clinical-Trial-of-its-CTLA-4-Checkpoint-Antibody-to-Treat-Solid-Tumors-04-27-2016 https://www.agenusbio.com/press/Agenus-Commences-Phase-1-Trial-with-Neoantigen-Cancer-Vaccine-AutoSynVax-04-05-2017 https://www.agenusbio.com/fr/press/Agenus-Commences-Phase-1-Trial-with-Neoantigen-Cancer-Vaccine-AutoSynVax-04-05-2017 https://www.agenusbio.com/es/press/Agenus-Commences-Phase-1-Trial-with-Neoantigen-Cancer-Vaccine-AutoSynVax-04-05-2017 https://www.agenusbio.com/press/Agenus-Commences-Phase-1-trial-with-AGEN1223-01-08-2020 https://www.agenusbio.com/fr/press/Agenus-Commences-Phase-1-trial-with-AGEN1223-01-08-2020 https://www.agenusbio.com/es/press/Agenus-Commences-Phase-1-trial-with-AGEN1223-01-08-2020 https://www.agenusbio.com/press/Agenus-Completes-Enrollment-in-Randomized-Phase-2-Clinical-Trial-of-BotensilimabBalstilimab-in-Advanced-Colorectal-Cancer https://www.agenusbio.com/fr/press/Agenus-Completes-Enrollment-in-Randomized-Phase-2-Clinical-Trial-of-BotensilimabBalstilimab-in-Advanced-Colorectal-Cancer https://www.agenusbio.com/es/press/Agenus-Completes-Enrollment-in-Randomized-Phase-2-Clinical-Trial-of-BotensilimabBalstilimab-in-Advanced-Colorectal-Cancer https://www.agenusbio.com/press/Agenus-Completes-Registered-Direct-Offering-09-19-2013 https://www.agenusbio.com/fr/press/Agenus-Completes-Registered-Direct-Offering-09-19-2013 https://www.agenusbio.com/es/press/Agenus-Completes-Registered-Direct-Offering-09-19-2013 https://www.agenusbio.com/press/Agenus-Completes-Registered-Direct-Offering-09-23-2013 https://www.agenusbio.com/fr/press/Agenus-Completes-Registered-Direct-Offering-09-23-2013 https://www.agenusbio.com/es/press/Agenus-Completes-Registered-Direct-Offering-09-23-2013 https://www.agenusbio.com/press/Agenus-Completes-XOMA-Antibody-Manufacturing-Pilot-Plant-Acquisition-01-04-2016 https://www.agenusbio.com/fr/press/Agenus-Completes-XOMA-Antibody-Manufacturing-Pilot-Plant-Acquisition-01-04-2016 https://www.agenusbio.com/es/press/Agenus-Completes-XOMA-Antibody-Manufacturing-Pilot-Plant-Acquisition-01-04-2016 https://www.agenusbio.com/press/Agenus-Corporate-Update-and-First-Quarter-2021-Financial-Report-05-06-2021 https://www.agenusbio.com/fr/press/Agenus-Corporate-Update-and-First-Quarter-2021-Financial-Report-05-06-2021 https://www.agenusbio.com/es/press/Agenus-Corporate-Update-and-First-Quarter-2021-Financial-Report-05-06-2021 https://www.agenusbio.com/press/Agenus-Corporate-Update-and-First-Quarter-2022-Financial-Report-05-10-2022 https://www.agenusbio.com/fr/press/Agenus-Corporate-Update-and-First-Quarter-2022-Financial-Report-05-10-2022 https://www.agenusbio.com/es/press/Agenus-Corporate-Update-and-First-Quarter-2022-Financial-Report-05-10-2022 https://www.agenusbio.com/press/Agenus-Corporate-Update-and-Fourth-Quarter-Full-Year-2020-Financial-Report-03-15-2021 https://www.agenusbio.com/fr/press/Agenus-Corporate-Update-and-Fourth-Quarter-Full-Year-2020-Financial-Report-03-15-2021 https://www.agenusbio.com/es/press/Agenus-Corporate-Update-and-Fourth-Quarter-Full-Year-2020-Financial-Report-03-15-2021 https://www.agenusbio.com/press/Agenus-Corporate-Update-and-Fourth-Quarter-Full-Year-2021-Financial-Report-03-01-2022 https://www.agenusbio.com/fr/press/Agenus-Corporate-Update-and-Fourth-Quarter-Full-Year-2021-Financial-Report-03-01-2022 https://www.agenusbio.com/es/press/Agenus-Corporate-Update-and-Fourth-Quarter-Full-Year-2021-Financial-Report-03-01-2022 https://www.agenusbio.com/press/Agenus-Corporate-Update-and-Second-Quarter-2021-Financial-Report-08-09-2021 https://www.agenusbio.com/fr/press/Agenus-Corporate-Update-and-Second-Quarter-2021-Financial-Report-08-09-2021 https://www.agenusbio.com/es/press/Agenus-Corporate-Update-and-Second-Quarter-2021-Financial-Report-08-09-2021 https://www.agenusbio.com/press/Agenus-Corporate-Update-and-Third-Quarter-2021-Financial-Report-11-09-2021 https://www.agenusbio.com/fr/press/Agenus-Corporate-Update-and-Third-Quarter-2021-Financial-Report-11-09-2021 https://www.agenusbio.com/es/press/Agenus-Corporate-Update-and-Third-Quarter-2021-Financial-Report-11-09-2021 https://www.agenusbio.com/press/Agenus-Data-at-CTOS-2022-Highlight-Durable-Clinical-Responses-of-Botensilimab--Balstilimab-Combination-in-Advanced-Sarcoma-11-17-2022 https://www.agenusbio.com/fr/press/Agenus-Data-at-CTOS-2022-Highlight-Durable-Clinical-Responses-of-Botensilimab--Balstilimab-Combination-in-Advanced-Sarcoma-11-17-2022 https://www.agenusbio.com/es/press/Agenus-Data-at-CTOS-2022-Highlight-Durable-Clinical-Responses-of-Botensilimab--Balstilimab-Combination-in-Advanced-Sarcoma-11-17-2022 https://www.agenusbio.com/press/Agenus-Data-at-SITC-2022-Highlight-Durable-Responses-of-Botensilimab--Balstilimab-Combination-in-Nine-Different-Treatment-Resistant-Cancers-11-14-2022 https://www.agenusbio.com/fr/press/Agenus-Data-at-SITC-2022-Highlight-Durable-Responses-of-Botensilimab--Balstilimab-Combination-in-Nine-Different-Treatment-Resistant-Cancers-11-14-2022 https://www.agenusbio.com/es/press/Agenus-Data-at-SITC-2022-Highlight-Durable-Responses-of-Botensilimab--Balstilimab-Combination-in-Nine-Different-Treatment-Resistant-Cancers-11-14-2022 https://www.agenusbio.com/press/Agenus-Discovery-Enhances-Activity-of-Cancer-Fighting-Antibodies-Findings-Published-in-Cancer-Cell-06-12-2018 https://www.agenusbio.com/fr/press/Agenus-Discovery-Enhances-Activity-of-Cancer-Fighting-Antibodies-Findings-Published-in-Cancer-Cell-06-12-2018 https://www.agenusbio.com/es/press/Agenus-Discovery-Enhances-Activity-of-Cancer-Fighting-Antibodies-Findings-Published-in-Cancer-Cell-06-12-2018 https://www.agenusbio.com/press/Agenus-Doses-First-COVID-19-Patient-with-iNKT-Cell-Therapy-11-02-2020 https://www.agenusbio.com/fr/press/Agenus-Doses-First-COVID-19-Patient-with-iNKT-Cell-Therapy-11-02-2020 https://www.agenusbio.com/es/press/Agenus-Doses-First-COVID-19-Patient-with-iNKT-Cell-Therapy-11-02-2020 https://www.agenusbio.com/press/Agenus-Doses-First-Cancer-Patient-with-iNKT-Cell-Therapy-04-14-2021 https://www.agenusbio.com/fr/press/Agenus-Doses-First-Cancer-Patient-with-iNKT-Cell-Therapy-04-14-2021 https://www.agenusbio.com/es/press/Agenus-Doses-First-Cancer-Patient-with-iNKT-Cell-Therapy-04-14-2021 https://www.agenusbio.com/press/Agenus-Enters-into-Clinical-Collaboration-with-Nelum-for-Zalifrelimab-Combination-01-26-2021 https://www.agenusbio.com/fr/press/Agenus-Enters-into-Clinical-Collaboration-with-Nelum-for-Zalifrelimab-Combination-01-26-2021 https://www.agenusbio.com/es/press/Agenus-Enters-into-Clinical-Collaboration-with-Nelum-for-Zalifrelimab-Combination-01-26-2021 https://www.agenusbio.com/press/Agenus-Enters-into-Definitive-Agreement-to-Acquire-Privately-Held-4-Antibody-AG-01-13-2014 https://www.agenusbio.com/fr/press/Agenus-Enters-into-Definitive-Agreement-to-Acquire-Privately-Held-4-Antibody-AG-01-13-2014 https://www.agenusbio.com/es/press/Agenus-Enters-into-Definitive-Agreement-to-Acquire-Privately-Held-4-Antibody-AG-01-13-2014 https://www.agenusbio.com/press/Agenus-Expands-Executive-Leadership-Team-07-20-2023 https://www.agenusbio.com/fr/press/Agenus-Expands-Executive-Leadership-Team-07-20-2023 https://www.agenusbio.com/es/press/Agenus-Expands-Executive-Leadership-Team-07-20-2023 https://www.agenusbio.com/press/Agenus-Expands-Medical-Affairs-Infrastructure-to-Support-Increasing-Physician-Requests-for-Authorized-Access-to-Botensilimab-Plus-Balstilimab-85f6a https://www.agenusbio.com/fr/press/Agenus-Expands-Medical-Affairs-Infrastructure-to-Support-Increasing-Physician-Requests-for-Authorized-Access-to-Botensilimab-Plus-Balstilimab-85f6a https://www.agenusbio.com/es/press/Agenus-Expands-Medical-Affairs-Infrastructure-to-Support-Increasing-Physician-Requests-for-Authorized-Access-to-Botensilimab-Plus-Balstilimab-85f6a https://www.agenusbio.com/press/Agenus-First-Quarter-Results-and-Update-05-07-2020 https://www.agenusbio.com/fr/press/Agenus-First-Quarter-Results-and-Update-05-07-2020 https://www.agenusbio.com/es/press/Agenus-First-Quarter-Results-and-Update-05-07-2020 https://www.agenusbio.com/press/Agenus-HerpV-Therapeutic-Vaccine-for-Genital-Herpes-Meets-Primary-Endpoint-in-Randomized-Phase-2-Trial-11-07-2013 https://www.agenusbio.com/fr/press/Agenus-HerpV-Therapeutic-Vaccine-for-Genital-Herpes-Meets-Primary-Endpoint-in-Randomized-Phase-2-Trial-11-07-2013 https://www.agenusbio.com/es/press/Agenus-HerpV-Therapeutic-Vaccine-for-Genital-Herpes-Meets-Primary-Endpoint-in-Randomized-Phase-2-Trial-11-07-2013 https://www.agenusbio.com/press/Agenus-Initiates-Botensilimab-Phase-2-ACTIVATE-Trials-in-Advanced-MSS-Colorectal-Cancer-and-Advanced-Melanoma-09-12-2022 https://www.agenusbio.com/fr/press/Agenus-Initiates-Botensilimab-Phase-2-ACTIVATE-Trials-in-Advanced-MSS-Colorectal-Cancer-and-Advanced-Melanoma-09-12-2022 https://www.agenusbio.com/es/press/Agenus-Initiates-Botensilimab-Phase-2-ACTIVATE-Trials-in-Advanced-MSS-Colorectal-Cancer-and-Advanced-Melanoma-09-12-2022 https://www.agenusbio.com/press/Agenus-Initiates-Rolling-BLA-Submission-of-Balstilimab-for-RecurrentMetastatic-Cervical-Cancer-09-18-2020 https://www.agenusbio.com/fr/press/Agenus-Initiates-Rolling-BLA-Submission-of-Balstilimab-for-RecurrentMetastatic-Cervical-Cancer-09-18-2020 https://www.agenusbio.com/es/press/Agenus-Initiates-Rolling-BLA-Submission-of-Balstilimab-for-RecurrentMetastatic-Cervical-Cancer-09-18-2020 https://www.agenusbio.com/press/Agenus-Launches-First-Asset-Backed-Digital-Security-Offering-in-Healthcare-02-19-2019 https://www.agenusbio.com/fr/press/Agenus-Launches-First-Asset-Backed-Digital-Security-Offering-in-Healthcare-02-19-2019 https://www.agenusbio.com/es/press/Agenus-Launches-First-Asset-Backed-Digital-Security-Offering-in-Healthcare-02-19-2019 https://www.agenusbio.com/press/Agenus-Launches-Phase-2-Trial-Expansion-in-Colon-Cancer-for-AGEN1181-in-Combination-with-Balstilimab-12-01-2020 https://www.agenusbio.com/fr/press/Agenus-Launches-Phase-2-Trial-Expansion-in-Colon-Cancer-for-AGEN1181-in-Combination-with-Balstilimab-12-01-2020 https://www.agenusbio.com/es/press/Agenus-Launches-Phase-2-Trial-Expansion-in-Colon-Cancer-for-AGEN1181-in-Combination-with-Balstilimab-12-01-2020 https://www.agenusbio.com/press/Agenus-Makes-Senior-Regulatory-and-Clinical-Appointments-09-12-2022 https://www.agenusbio.com/fr/press/Agenus-Makes-Senior-Regulatory-and-Clinical-Appointments-09-12-2022 https://www.agenusbio.com/es/press/Agenus-Makes-Senior-Regulatory-and-Clinical-Appointments-09-12-2022 https://www.agenusbio.com/press/Agenus-NextGen-CTLA-4-Antibody-AGEN1181-Data-to-be-Presented-at-ASCO-05-14-2020 https://www.agenusbio.com/fr/press/Agenus-NextGen-CTLA-4-Antibody-AGEN1181-Data-to-be-Presented-at-ASCO-05-14-2020 https://www.agenusbio.com/es/press/Agenus-NextGen-CTLA-4-Antibody-AGEN1181-Data-to-be-Presented-at-ASCO-05-14-2020 https://www.agenusbio.com/press/Agenus-Presentations-at-ASCO-2021-Demonstrate-Differentiated-Activity-of-Balstilimab-and-Provide-Clinical-Update-on-AGEN2373-06-04-2021 https://www.agenusbio.com/fr/press/Agenus-Presentations-at-ASCO-2021-Demonstrate-Differentiated-Activity-of-Balstilimab-and-Provide-Clinical-Update-on-AGEN2373-06-04-2021 https://www.agenusbio.com/es/press/Agenus-Presentations-at-ASCO-2021-Demonstrate-Differentiated-Activity-of-Balstilimab-and-Provide-Clinical-Update-on-AGEN2373-06-04-2021 https://www.agenusbio.com/press/Agenus-Presents-Additional-Clinical-Responses-and-Novel-Biomarker-Data-at-SITC2020-11-09-2020 https://www.agenusbio.com/fr/press/Agenus-Presents-Additional-Clinical-Responses-and-Novel-Biomarker-Data-at-SITC2020-11-09-2020 https://www.agenusbio.com/es/press/Agenus-Presents-Additional-Clinical-Responses-and-Novel-Biomarker-Data-at-SITC2020-11-09-2020 https://www.agenusbio.com/press/Agenus-Presents-Clinical-Data-Demonstrating-Durable-Responses-of-BotensilimabBalstilimab-Combination-in-Metastatic-Microsatellite-Stable-Colorectal-Cancer-at-ASCO-GI-01-23-2023 https://www.agenusbio.com/fr/press/Agenus-Presents-Clinical-Data-Demonstrating-Durable-Responses-of-BotensilimabBalstilimab-Combination-in-Metastatic-Microsatellite-Stable-Colorectal-Cancer-at-ASCO-GI-01-23-2023 https://www.agenusbio.com/es/press/Agenus-Presents-Clinical-Data-Demonstrating-Durable-Responses-of-BotensilimabBalstilimab-Combination-in-Metastatic-Microsatellite-Stable-Colorectal-Cancer-at-ASCO-GI-01-23-2023 https://www.agenusbio.com/press/Agenus-Presents-Clinical-Data-on-Its-PD-1-CTLA-4-at-ESMO-2018-10-20-2018 https://www.agenusbio.com/fr/press/Agenus-Presents-Clinical-Data-on-Its-PD-1-CTLA-4-at-ESMO-2018-10-20-2018 https://www.agenusbio.com/es/press/Agenus-Presents-Clinical-Data-on-Its-PD-1-CTLA-4-at-ESMO-2018-10-20-2018 https://www.agenusbio.com/press/Agenus-Presents-Clinical-Responses-of-AGEN1884-anti-CTLA-4-and-AGEN2034-anti-PD-1-at-ASCO-2018-06-04-2018 https://www.agenusbio.com/fr/press/Agenus-Presents-Clinical-Responses-of-AGEN1884-anti-CTLA-4-and-AGEN2034-anti-PD-1-at-ASCO-2018-06-04-2018 https://www.agenusbio.com/es/press/Agenus-Presents-Clinical-Responses-of-AGEN1884-anti-CTLA-4-and-AGEN2034-anti-PD-1-at-ASCO-2018-06-04-2018 https://www.agenusbio.com/press/Agenus-Presents-Data-at-ASCO-GI-Demonstrating-Impact-of-BOTBAL-in-Colorectal-Cancer-Across-Neoadjuvant-and-Advanced-Disease https://www.agenusbio.com/fr/press/Agenus-Presents-Data-at-ASCO-GI-Demonstrating-Impact-of-BOTBAL-in-Colorectal-Cancer-Across-Neoadjuvant-and-Advanced-Disease https://www.agenusbio.com/es/press/Agenus-Presents-Data-at-ASCO-GI-Demonstrating-Impact-of-BOTBAL-in-Colorectal-Cancer-Across-Neoadjuvant-and-Advanced-Disease https://www.agenusbio.com/press/Agenus-Presents-Data-on-AGEN1571-anti-ILT2-at-AACR-and-Announces-IND-Clearance-04-08-2022 https://www.agenusbio.com/fr/press/Agenus-Presents-Data-on-AGEN1571-anti-ILT2-at-AACR-and-Announces-IND-Clearance-04-08-2022 https://www.agenusbio.com/es/press/Agenus-Presents-Data-on-AGEN1571-anti-ILT2-at-AACR-and-Announces-IND-Clearance-04-08-2022 https://www.agenusbio.com/press/Agenus-Presents-New-BotensilimabBalstilimab-Data-in-Gastric-Cancer-at-AACR-IO-Annual-Meeting https://www.agenusbio.com/fr/press/Agenus-Presents-New-BotensilimabBalstilimab-Data-in-Gastric-Cancer-at-AACR-IO-Annual-Meeting https://www.agenusbio.com/es/press/Agenus-Presents-New-BotensilimabBalstilimab-Data-in-Gastric-Cancer-at-AACR-IO-Annual-Meeting https://www.agenusbio.com/press/Agenus-Presents-New-Data-at-ASCO-Highlighting-Botensilimabs-Immune-Activation-in-MSS-Colorectal-Cancer https://www.agenusbio.com/fr/press/Agenus-Presents-New-Data-at-ASCO-Highlighting-Botensilimabs-Immune-Activation-in-MSS-Colorectal-Cancer https://www.agenusbio.com/es/press/Agenus-Presents-New-Data-at-ASCO-Highlighting-Botensilimabs-Immune-Activation-in-MSS-Colorectal-Cancer https://www.agenusbio.com/press/Agenus-Presents-New-Data-on-Balstilimab-and-AGEN2373-in-ASCO-Abstracts-05-20-2021 https://www.agenusbio.com/fr/press/Agenus-Presents-New-Data-on-Balstilimab-and-AGEN2373-in-ASCO-Abstracts-05-20-2021 https://www.agenusbio.com/es/press/Agenus-Presents-New-Data-on-Balstilimab-and-AGEN2373-in-ASCO-Abstracts-05-20-2021 https://www.agenusbio.com/press/Agenus-Presents-Positive-Efficacy-and-Safety-Outcomes-for-AGEN2373-at-ASCO-06-05-2023 https://www.agenusbio.com/fr/press/Agenus-Presents-Positive-Efficacy-and-Safety-Outcomes-for-AGEN2373-at-ASCO-06-05-2023 https://www.agenusbio.com/es/press/Agenus-Presents-Positive-Efficacy-and-Safety-Outcomes-for-AGEN2373-at-ASCO-06-05-2023 https://www.agenusbio.com/press/Agenus-Presents-Posters-on-Checkpoint-Antibody-Product-Candidates-at-the-American-Association-for-Cancer-Research-AACR-2016-Annual-Meeting-04-18-2016 https://www.agenusbio.com/fr/press/Agenus-Presents-Posters-on-Checkpoint-Antibody-Product-Candidates-at-the-American-Association-for-Cancer-Research-AACR-2016-Annual-Meeting-04-18-2016 https://www.agenusbio.com/es/press/Agenus-Presents-Posters-on-Checkpoint-Antibody-Product-Candidates-at-the-American-Association-for-Cancer-Research-AACR-2016-Annual-Meeting-04-18-2016 https://www.agenusbio.com/press/Agenus-Presents-Results-from-Two-Large-Cervical-Cancer-Trials-at-ESMO-09-18-2020 https://www.agenusbio.com/fr/press/Agenus-Presents-Results-from-Two-Large-Cervical-Cancer-Trials-at-ESMO-09-18-2020 https://www.agenusbio.com/es/press/Agenus-Presents-Results-from-Two-Large-Cervical-Cancer-Trials-at-ESMO-09-18-2020 https://www.agenusbio.com/press/Agenus-Prices-Public-Offering-of-Common-Stock-02-05-2014 https://www.agenusbio.com/fr/press/Agenus-Prices-Public-Offering-of-Common-Stock-02-05-2014 https://www.agenusbio.com/es/press/Agenus-Prices-Public-Offering-of-Common-Stock-02-05-2014 https://www.agenusbio.com/press/Agenus-Prioritizes-Resources-to-Accelerate-Registration-and-Commercialization-of-BOTBAL-Program-in-Multiple-Cancers https://www.agenusbio.com/fr/press/Agenus-Prioritizes-Resources-to-Accelerate-Registration-and-Commercialization-of-BOTBAL-Program-in-Multiple-Cancers https://www.agenusbio.com/es/press/Agenus-Prioritizes-Resources-to-Accelerate-Registration-and-Commercialization-of-BOTBAL-Program-in-Multiple-Cancers https://www.agenusbio.com/press/Agenus-Provides-Corporate-Update-and-First-Quarter-2023-Financial-Results-05-09-2023 https://www.agenusbio.com/fr/press/Agenus-Provides-Corporate-Update-and-First-Quarter-2023-Financial-Results-05-09-2023 https://www.agenusbio.com/es/press/Agenus-Provides-Corporate-Update-and-First-Quarter-2023-Financial-Results-05-09-2023 https://www.agenusbio.com/press/Agenus-Provides-Corporate-Update-and-Second-Quarter-2022-Financial-Report-08-09-2022 https://www.agenusbio.com/fr/press/Agenus-Provides-Corporate-Update-and-Second-Quarter-2022-Financial-Report-08-09-2022 https://www.agenusbio.com/es/press/Agenus-Provides-Corporate-Update-and-Second-Quarter-2022-Financial-Report-08-09-2022 https://www.agenusbio.com/press/Agenus-Provides-Corporate-Update-and-Third-Quarter-2022-Financial-Report-11-08-2022 https://www.agenusbio.com/fr/press/Agenus-Provides-Corporate-Update-and-Third-Quarter-2022-Financial-Report-11-08-2022 https://www.agenusbio.com/es/press/Agenus-Provides-Corporate-Update-and-Third-Quarter-2022-Financial-Report-11-08-2022 https://www.agenusbio.com/press/Agenus-Provides-Corporate-Update-with-Third-Quarter-2019-Financial-Results-11-04-2019 https://www.agenusbio.com/fr/press/Agenus-Provides-Corporate-Update-with-Third-Quarter-2019-Financial-Results-11-04-2019 https://www.agenusbio.com/es/press/Agenus-Provides-Corporate-Update-with-Third-Quarter-2019-Financial-Results-11-04-2019 https://www.agenusbio.com/press/Agenus-Provides-RD-Update-Second-Quarter-Financial-Report-08-06-2020 https://www.agenusbio.com/fr/press/Agenus-Provides-RD-Update-Second-Quarter-Financial-Report-08-06-2020 https://www.agenusbio.com/es/press/Agenus-Provides-RD-Update-Second-Quarter-Financial-Report-08-06-2020 https://www.agenusbio.com/press/Agenus-Provides-Update-on-Balstilimab-Development-10-22-2021 https://www.agenusbio.com/fr/press/Agenus-Provides-Update-on-Balstilimab-Development-10-22-2021 https://www.agenusbio.com/es/press/Agenus-Provides-Update-on-Balstilimab-Development-10-22-2021 https://www.agenusbio.com/press/Agenus-Publishes-Seminal-Study-on-Botensilimabs-Activity-in-Treatment-Resistant-Cancers https://www.agenusbio.com/fr/press/Agenus-Publishes-Seminal-Study-on-Botensilimabs-Activity-in-Treatment-Resistant-Cancers https://www.agenusbio.com/es/press/Agenus-Publishes-Seminal-Study-on-Botensilimabs-Activity-in-Treatment-Resistant-Cancers https://www.agenusbio.com/press/Agenus-RD-Update-Third-Quarter-Financial-Report-10-29-2020 https://www.agenusbio.com/fr/press/Agenus-RD-Update-Third-Quarter-Financial-Report-10-29-2020 https://www.agenusbio.com/es/press/Agenus-RD-Update-Third-Quarter-Financial-Report-10-29-2020 https://www.agenusbio.com/press/Agenus-RD-Update-to-Be-Held-on-November-19-2015-11-12-2015 https://www.agenusbio.com/fr/press/Agenus-RD-Update-to-Be-Held-on-November-19-2015-11-12-2015 https://www.agenusbio.com/es/press/Agenus-RD-Update-to-Be-Held-on-November-19-2015-11-12-2015 https://www.agenusbio.com/press/Agenus-RD-update-Second-Quarter-Earnings-Report-07-29-2020 https://www.agenusbio.com/fr/press/Agenus-RD-update-Second-Quarter-Earnings-Report-07-29-2020 https://www.agenusbio.com/es/press/Agenus-RD-update-Second-Quarter-Earnings-Report-07-29-2020 https://www.agenusbio.com/press/Agenus-Receives-35M-In-Immuno-Oncology-Transaction-with-Betta-Pharmaceuticals-07-28-2020 https://www.agenusbio.com/fr/press/Agenus-Receives-35M-In-Immuno-Oncology-Transaction-with-Betta-Pharmaceuticals-07-28-2020 https://www.agenusbio.com/es/press/Agenus-Receives-35M-In-Immuno-Oncology-Transaction-with-Betta-Pharmaceuticals-07-28-2020 https://www.agenusbio.com/press/Agenus-Receives-Fast-Track-Designation-for-Balstilimab-Zalifrelimab-in-Advanced-Cervical-Cancer-03-12-2020 https://www.agenusbio.com/fr/press/Agenus-Receives-Fast-Track-Designation-for-Balstilimab-Zalifrelimab-in-Advanced-Cervical-Cancer-03-12-2020 https://www.agenusbio.com/es/press/Agenus-Receives-Fast-Track-Designation-for-Balstilimab-Zalifrelimab-in-Advanced-Cervical-Cancer-03-12-2020 https://www.agenusbio.com/press/Agenus-Receives-Fast-Track-Designation-for-Balstilimab-in-Advanced-Cervical-Cancer-04-07-2020 https://www.agenusbio.com/fr/press/Agenus-Receives-Fast-Track-Designation-for-Balstilimab-in-Advanced-Cervical-Cancer-04-07-2020 https://www.agenusbio.com/es/press/Agenus-Receives-Fast-Track-Designation-for-Balstilimab-in-Advanced-Cervical-Cancer-04-07-2020 https://www.agenusbio.com/press/Agenus-Receives-Fast-Track-Designation-for-Botensilimab-and-Balstilimab-in-Colorectal-Cancer-04-17-2023 https://www.agenusbio.com/fr/press/Agenus-Receives-Fast-Track-Designation-for-Botensilimab-and-Balstilimab-in-Colorectal-Cancer-04-17-2023 https://www.agenusbio.com/es/press/Agenus-Receives-Fast-Track-Designation-for-Botensilimab-and-Balstilimab-in-Colorectal-Cancer-04-17-2023 https://www.agenusbio.com/press/Agenus-Receives-License-Fee-of-4-Million-USD-from-Merck-11-15-2017 https://www.agenusbio.com/fr/press/Agenus-Receives-License-Fee-of-4-Million-USD-from-Merck-11-15-2017 https://www.agenusbio.com/es/press/Agenus-Receives-License-Fee-of-4-Million-USD-from-Merck-11-15-2017 https://www.agenusbio.com/press/Agenus-Receives-Milestone-Payment-from-Incyte-09-17-2018 https://www.agenusbio.com/fr/press/Agenus-Receives-Milestone-Payment-from-Incyte-09-17-2018 https://www.agenusbio.com/es/press/Agenus-Receives-Milestone-Payment-from-Incyte-09-17-2018 https://www.agenusbio.com/press/Agenus-Receives-Second-Milestone-Payment-from-Merck-08-15-2018 https://www.agenusbio.com/fr/press/Agenus-Receives-Second-Milestone-Payment-from-Merck-08-15-2018 https://www.agenusbio.com/es/press/Agenus-Receives-Second-Milestone-Payment-from-Merck-08-15-2018 https://www.agenusbio.com/press/Agenus-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement https://www.agenusbio.com/fr/press/Agenus-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement https://www.agenusbio.com/es/press/Agenus-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement https://www.agenusbio.com/press/Agenus-Reports-39-of-Patients-Alive-at-Two-Years-with-BOTBAL-Across-Multiple-Refractory-Solid-Tumors-at-ESMO-2025-591f8 https://www.agenusbio.com/fr/press/Agenus-Reports-39-of-Patients-Alive-at-Two-Years-with-BOTBAL-Across-Multiple-Refractory-Solid-Tumors-at-ESMO-2025-591f8 https://www.agenusbio.com/es/press/Agenus-Reports-39-of-Patients-Alive-at-Two-Years-with-BOTBAL-Across-Multiple-Refractory-Solid-Tumors-at-ESMO-2025-591f8 https://www.agenusbio.com/press/Agenus-Reports-Deep-Durable-Responses-with-Botensilimab--Balstilimab-in-Highly-Refractory-Ovarian-Cancer-Published-in-JITC-c4e15 https://www.agenusbio.com/fr/press/Agenus-Reports-Deep-Durable-Responses-with-Botensilimab--Balstilimab-in-Highly-Refractory-Ovarian-Cancer-Published-in-JITC-c4e15 https://www.agenusbio.com/es/press/Agenus-Reports-Deep-Durable-Responses-with-Botensilimab--Balstilimab-in-Highly-Refractory-Ovarian-Cancer-Published-in-JITC-c4e15 https://www.agenusbio.com/press/Agenus-Reports-First-Quarter-2013-Financial-Results-04-24-2013 https://www.agenusbio.com/fr/press/Agenus-Reports-First-Quarter-2013-Financial-Results-04-24-2013 https://www.agenusbio.com/es/press/Agenus-Reports-First-Quarter-2013-Financial-Results-04-24-2013 https://www.agenusbio.com/press/Agenus-Reports-First-Quarter-2014-Financial-Results-05-08-2014 https://www.agenusbio.com/fr/press/Agenus-Reports-First-Quarter-2014-Financial-Results-05-08-2014 https://www.agenusbio.com/es/press/Agenus-Reports-First-Quarter-2014-Financial-Results-05-08-2014 https://www.agenusbio.com/press/Agenus-Reports-First-Quarter-2015-Financial-Results-04-23-2015 https://www.agenusbio.com/fr/press/Agenus-Reports-First-Quarter-2015-Financial-Results-04-23-2015 https://www.agenusbio.com/es/press/Agenus-Reports-First-Quarter-2015-Financial-Results-04-23-2015 https://www.agenusbio.com/press/Agenus-Reports-First-Quarter-2016-Financial-Results-and-Operational-Progress-04-28-2016 https://www.agenusbio.com/fr/press/Agenus-Reports-First-Quarter-2016-Financial-Results-and-Operational-Progress-04-28-2016 https://www.agenusbio.com/es/press/Agenus-Reports-First-Quarter-2016-Financial-Results-and-Operational-Progress-04-28-2016 https://www.agenusbio.com/press/Agenus-Reports-First-Quarter-2017-Financial-Results-and-Provides-Corporate-Update-05-04-2017 https://www.agenusbio.com/fr/press/Agenus-Reports-First-Quarter-2017-Financial-Results-and-Provides-Corporate-Update-05-04-2017 https://www.agenusbio.com/es/press/Agenus-Reports-First-Quarter-2017-Financial-Results-and-Provides-Corporate-Update-05-04-2017 https://www.agenusbio.com/press/Agenus-Reports-First-Quarter-2018-Financial-Results-and-Provides-Corporate-Update-05-07-2018 https://www.agenusbio.com/fr/press/Agenus-Reports-First-Quarter-2018-Financial-Results-and-Provides-Corporate-Update-05-07-2018 https://www.agenusbio.com/es/press/Agenus-Reports-First-Quarter-2018-Financial-Results-and-Provides-Corporate-Update-05-07-2018 https://www.agenusbio.com/press/Agenus-Reports-First-Quarter-2019-Financial-Results-and-Provides-Corporate-Update-05-09-2019 https://www.agenusbio.com/fr/press/Agenus-Reports-First-Quarter-2019-Financial-Results-and-Provides-Corporate-Update-05-09-2019 https://www.agenusbio.com/es/press/Agenus-Reports-First-Quarter-2019-Financial-Results-and-Provides-Corporate-Update-05-09-2019 https://www.agenusbio.com/press/Agenus-Reports-First-Quarter-2024-Results https://www.agenusbio.com/fr/press/Agenus-Reports-First-Quarter-2024-Results https://www.agenusbio.com/es/press/Agenus-Reports-First-Quarter-2024-Results https://www.agenusbio.com/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2013-Financial-Results-03-05-2014 https://www.agenusbio.com/fr/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2013-Financial-Results-03-05-2014 https://www.agenusbio.com/es/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2013-Financial-Results-03-05-2014 https://www.agenusbio.com/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2014-Financial-Results-02-26-2015 https://www.agenusbio.com/fr/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2014-Financial-Results-02-26-2015 https://www.agenusbio.com/es/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2014-Financial-Results-02-26-2015 https://www.agenusbio.com/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2015-Financial-and-Operational-Results-and-Recent-Highlights-03-03-2016 https://www.agenusbio.com/fr/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2015-Financial-and-Operational-Results-and-Recent-Highlights-03-03-2016 https://www.agenusbio.com/es/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2015-Financial-and-Operational-Results-and-Recent-Highlights-03-03-2016 https://www.agenusbio.com/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2016-Results-03-09-2017 https://www.agenusbio.com/fr/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2016-Results-03-09-2017 https://www.agenusbio.com/es/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2016-Results-03-09-2017 https://www.agenusbio.com/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2017-Financial-Results-and-Provides-Corporate-Update-03-15-2018 https://www.agenusbio.com/fr/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2017-Financial-Results-and-Provides-Corporate-Update-03-15-2018 https://www.agenusbio.com/es/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2017-Financial-Results-and-Provides-Corporate-Update-03-15-2018 https://www.agenusbio.com/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2018-Financial-Results-and-Provides-Corporate-Update-03-14-2019 https://www.agenusbio.com/fr/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2018-Financial-Results-and-Provides-Corporate-Update-03-14-2019 https://www.agenusbio.com/es/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2018-Financial-Results-and-Provides-Corporate-Update-03-14-2019 https://www.agenusbio.com/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results-and-Provides-Corporate-Update-03-12-2020 https://www.agenusbio.com/fr/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results-and-Provides-Corporate-Update-03-12-2020 https://www.agenusbio.com/es/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2019-Financial-Results-and-Provides-Corporate-Update-03-12-2020 https://www.agenusbio.com/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Outlines-2023-Objectives-03-14-2023 https://www.agenusbio.com/fr/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Outlines-2023-Objectives-03-14-2023 https://www.agenusbio.com/es/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Outlines-2023-Objectives-03-14-2023 https://www.agenusbio.com/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2023-Results https://www.agenusbio.com/fr/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2023-Results https://www.agenusbio.com/es/press/Agenus-Reports-Fourth-Quarter-and-Full-Year-2023-Results https://www.agenusbio.com/press/Agenus-Reports-Impact-of-Key-Immuno-Oncology-Data-Presented-at-Leading-Medical-Conferences-and-Peer-Reviewed-Publications https://www.agenusbio.com/fr/press/Agenus-Reports-Impact-of-Key-Immuno-Oncology-Data-Presented-at-Leading-Medical-Conferences-and-Peer-Reviewed-Publications https://www.agenusbio.com/es/press/Agenus-Reports-Impact-of-Key-Immuno-Oncology-Data-Presented-at-Leading-Medical-Conferences-and-Peer-Reviewed-Publications https://www.agenusbio.com/press/Agenus-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635c4-01-14-2016 https://www.agenusbio.com/fr/press/Agenus-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635c4-01-14-2016 https://www.agenusbio.com/es/press/Agenus-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635c4-01-14-2016 https://www.agenusbio.com/press/Agenus-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4 https://www.agenusbio.com/fr/press/Agenus-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4 https://www.agenusbio.com/es/press/Agenus-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4 https://www.agenusbio.com/press/Agenus-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-078299ec9 https://www.agenusbio.com/fr/press/Agenus-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-078299ec9 https://www.agenusbio.com/es/press/Agenus-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-078299ec9 https://www.agenusbio.com/press/Agenus-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-32b9c7205 https://www.agenusbio.com/fr/press/Agenus-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-32b9c7205 https://www.agenusbio.com/es/press/Agenus-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4-32b9c7205 https://www.agenusbio.com/press/Agenus-Reports-Positive-Follow-on-Phase-2-Results-for-Brain-Cancer-Vaccine-in-Newly-Diagnosed-Patients-09-17-2013 https://www.agenusbio.com/fr/press/Agenus-Reports-Positive-Follow-on-Phase-2-Results-for-Brain-Cancer-Vaccine-in-Newly-Diagnosed-Patients-09-17-2013 https://www.agenusbio.com/es/press/Agenus-Reports-Positive-Follow-on-Phase-2-Results-for-Brain-Cancer-Vaccine-in-Newly-Diagnosed-Patients-09-17-2013 https://www.agenusbio.com/press/Agenus-Reports-Q1-2025-Financial-Results-and-Key-Business-Updates https://www.agenusbio.com/fr/press/Agenus-Reports-Q1-2025-Financial-Results-and-Key-Business-Updates https://www.agenusbio.com/es/press/Agenus-Reports-Q1-2025-Financial-Results-and-Key-Business-Updates https://www.agenusbio.com/press/Agenus-Reports-Q3-2025-Results-Showcasing-Clinical-and-Regulatory-Advances-eccc2 https://www.agenusbio.com/fr/press/Agenus-Reports-Q3-2025-Results-Showcasing-Clinical-and-Regulatory-Advances-eccc2 https://www.agenusbio.com/es/press/Agenus-Reports-Q3-2025-Results-Showcasing-Clinical-and-Regulatory-Advances-eccc2 https://www.agenusbio.com/press/Agenus-Reports-Q4-and-Year-End-2024-Results-Strategic-Operational-Improvements-and-Significant-Cost-Reductions-Enhance-Sustainability-of-Promising-BOTBAL-Program https://www.agenusbio.com/fr/press/Agenus-Reports-Q4-and-Year-End-2024-Results-Strategic-Operational-Improvements-and-Significant-Cost-Reductions-Enhance-Sustainability-of-Promising-BOTBAL-Program https://www.agenusbio.com/es/press/Agenus-Reports-Q4-and-Year-End-2024-Results-Strategic-Operational-Improvements-and-Significant-Cost-Reductions-Enhance-Sustainability-of-Promising-BOTBAL-Program https://www.agenusbio.com/press/Agenus-Reports-Second-Quarter-2014-Financial-Results-07-24-2014 https://www.agenusbio.com/fr/press/Agenus-Reports-Second-Quarter-2014-Financial-Results-07-24-2014 https://www.agenusbio.com/es/press/Agenus-Reports-Second-Quarter-2014-Financial-Results-07-24-2014 https://www.agenusbio.com/press/Agenus-Reports-Second-Quarter-2015-Financial-Results-07-23-2015 https://www.agenusbio.com/fr/press/Agenus-Reports-Second-Quarter-2015-Financial-Results-07-23-2015 https://www.agenusbio.com/es/press/Agenus-Reports-Second-Quarter-2015-Financial-Results-07-23-2015 https://www.agenusbio.com/press/Agenus-Reports-Second-Quarter-2016-Financial-Results-and-Operational-Progress-07-28-2016 https://www.agenusbio.com/fr/press/Agenus-Reports-Second-Quarter-2016-Financial-Results-and-Operational-Progress-07-28-2016 https://www.agenusbio.com/es/press/Agenus-Reports-Second-Quarter-2016-Financial-Results-and-Operational-Progress-07-28-2016 https://www.agenusbio.com/press/Agenus-Reports-Second-Quarter-2017-Financial-Results-and-Provides-Corporate-Update-08-03-2017 https://www.agenusbio.com/fr/press/Agenus-Reports-Second-Quarter-2017-Financial-Results-and-Provides-Corporate-Update-08-03-2017 https://www.agenusbio.com/es/press/Agenus-Reports-Second-Quarter-2017-Financial-Results-and-Provides-Corporate-Update-08-03-2017 https://www.agenusbio.com/press/Agenus-Reports-Second-Quarter-2018-Financial-Results-and-Provides-Corporate-Update-08-09-2018 https://www.agenusbio.com/fr/press/Agenus-Reports-Second-Quarter-2018-Financial-Results-and-Provides-Corporate-Update-08-09-2018 https://www.agenusbio.com/es/press/Agenus-Reports-Second-Quarter-2018-Financial-Results-and-Provides-Corporate-Update-08-09-2018 https://www.agenusbio.com/press/Agenus-Reports-Second-Quarter-2019-Financial-Results-and-Provides-Corporate-Update-08-08-2019 https://www.agenusbio.com/fr/press/Agenus-Reports-Second-Quarter-2019-Financial-Results-and-Provides-Corporate-Update-08-08-2019 https://www.agenusbio.com/es/press/Agenus-Reports-Second-Quarter-2019-Financial-Results-and-Provides-Corporate-Update-08-08-2019 https://www.agenusbio.com/press/Agenus-Reports-Second-Quarter-2023-Results https://www.agenusbio.com/fr/press/Agenus-Reports-Second-Quarter-2023-Results https://www.agenusbio.com/es/press/Agenus-Reports-Second-Quarter-2023-Results https://www.agenusbio.com/press/Agenus-Reports-Second-Quarter-2024-Operational-and-Financial-Results https://www.agenusbio.com/fr/press/Agenus-Reports-Second-Quarter-2024-Operational-and-Financial-Results https://www.agenusbio.com/es/press/Agenus-Reports-Second-Quarter-2024-Operational-and-Financial-Results https://www.agenusbio.com/press/Agenus-Reports-Third-Quarter-2013-Financial-Results-10-24-2013 https://www.agenusbio.com/fr/press/Agenus-Reports-Third-Quarter-2013-Financial-Results-10-24-2013 https://www.agenusbio.com/es/press/Agenus-Reports-Third-Quarter-2013-Financial-Results-10-24-2013 https://www.agenusbio.com/press/Agenus-Reports-Third-Quarter-2014-Financial-Results-10-31-2014 https://www.agenusbio.com/fr/press/Agenus-Reports-Third-Quarter-2014-Financial-Results-10-31-2014 https://www.agenusbio.com/es/press/Agenus-Reports-Third-Quarter-2014-Financial-Results-10-31-2014 https://www.agenusbio.com/press/Agenus-Reports-Third-Quarter-2015-Financial-Results-10-27-2015 https://www.agenusbio.com/fr/press/Agenus-Reports-Third-Quarter-2015-Financial-Results-10-27-2015 https://www.agenusbio.com/es/press/Agenus-Reports-Third-Quarter-2015-Financial-Results-10-27-2015 https://www.agenusbio.com/press/Agenus-Reports-Third-Quarter-2017-Financial-Results-and-Provides-Corporate-Update-11-07-2017 https://www.agenusbio.com/fr/press/Agenus-Reports-Third-Quarter-2017-Financial-Results-and-Provides-Corporate-Update-11-07-2017 https://www.agenusbio.com/es/press/Agenus-Reports-Third-Quarter-2017-Financial-Results-and-Provides-Corporate-Update-11-07-2017 https://www.agenusbio.com/press/Agenus-Reports-Third-Quarter-2018-Financial-Results-and-Provides-Corporate-Update-11-06-2018 https://www.agenusbio.com/fr/press/Agenus-Reports-Third-Quarter-2018-Financial-Results-and-Provides-Corporate-Update-11-06-2018 https://www.agenusbio.com/es/press/Agenus-Reports-Third-Quarter-2018-Financial-Results-and-Provides-Corporate-Update-11-06-2018 https://www.agenusbio.com/press/Agenus-Reports-Third-Quarter-2023-Results https://www.agenusbio.com/fr/press/Agenus-Reports-Third-Quarter-2023-Results https://www.agenusbio.com/es/press/Agenus-Reports-Third-Quarter-2023-Results https://www.agenusbio.com/press/Agenus-Reports-Third-Quarter-2024-Financial-Results-and-Strategic-Advancements-in-BOTBAL-Development https://www.agenusbio.com/fr/press/Agenus-Reports-Third-Quarter-2024-Financial-Results-and-Strategic-Advancements-in-BOTBAL-Development https://www.agenusbio.com/es/press/Agenus-Reports-Third-Quarter-2024-Financial-Results-and-Strategic-Advancements-in-BOTBAL-Development https://www.agenusbio.com/press/Agenus-Reports-Third-Quarter-Financial-Results-and-Recent-Highlights-10-27-2016 https://www.agenusbio.com/fr/press/Agenus-Reports-Third-Quarter-Financial-Results-and-Recent-Highlights-10-27-2016 https://www.agenusbio.com/es/press/Agenus-Reports-Third-Quarter-Financial-Results-and-Recent-Highlights-10-27-2016 https://www.agenusbio.com/press/Agenus-Schedules-Conference-Call-to-Discuss-the-Companys-Minority-Cash-Holdings-at-SVB-03-11-2023 https://www.agenusbio.com/fr/press/Agenus-Schedules-Conference-Call-to-Discuss-the-Companys-Minority-Cash-Holdings-at-SVB-03-11-2023 https://www.agenusbio.com/es/press/Agenus-Schedules-Conference-Call-to-Discuss-the-Companys-Minority-Cash-Holdings-at-SVB-03-11-2023 https://www.agenusbio.com/press/Agenus-Secures-22-Million-Mortgage-and-Announces-Strategic-Operational-Realignment https://www.agenusbio.com/fr/press/Agenus-Secures-22-Million-Mortgage-and-Announces-Strategic-Operational-Realignment https://www.agenusbio.com/es/press/Agenus-Secures-22-Million-Mortgage-and-Announces-Strategic-Operational-Realignment https://www.agenusbio.com/press/Agenus-Selected-for-Inclusion-in-the-Russell-3000-Index-and-Global-Index-06-16-2014 https://www.agenusbio.com/fr/press/Agenus-Selected-for-Inclusion-in-the-Russell-3000-Index-and-Global-Index-06-16-2014 https://www.agenusbio.com/es/press/Agenus-Selected-for-Inclusion-in-the-Russell-3000-Index-and-Global-Index-06-16-2014 https://www.agenusbio.com/press/Agenus-Selected-for-Late-Breaking-Oral-Presentation-at-ESMO-GI-05-03-2023 https://www.agenusbio.com/fr/press/Agenus-Selected-for-Late-Breaking-Oral-Presentation-at-ESMO-GI-05-03-2023 https://www.agenusbio.com/es/press/Agenus-Selected-for-Late-Breaking-Oral-Presentation-at-ESMO-GI-05-03-2023 https://www.agenusbio.com/press/Agenus-Shows-Unprecedented-Activity-for-BotensilimabBalstilimab-Combination-in-Microsatellite-Stable-Colorectal-Cancer-at-ESMO-World-GI-Congress-06-29-2022 https://www.agenusbio.com/fr/press/Agenus-Shows-Unprecedented-Activity-for-BotensilimabBalstilimab-Combination-in-Microsatellite-Stable-Colorectal-Cancer-at-ESMO-World-GI-Congress-06-29-2022 https://www.agenusbio.com/es/press/Agenus-Shows-Unprecedented-Activity-for-BotensilimabBalstilimab-Combination-in-Microsatellite-Stable-Colorectal-Cancer-at-ESMO-World-GI-Congress-06-29-2022 https://www.agenusbio.com/press/Agenus-To-Advance-Three-Checkpoint-Modulator-Antibodies-Into-Development-03-05-2014 https://www.agenusbio.com/fr/press/Agenus-To-Advance-Three-Checkpoint-Modulator-Antibodies-Into-Development-03-05-2014 https://www.agenusbio.com/es/press/Agenus-To-Advance-Three-Checkpoint-Modulator-Antibodies-Into-Development-03-05-2014 https://www.agenusbio.com/press/Agenus-To-Host-BOTBAL-Program-Update-at-ESMO-2023 https://www.agenusbio.com/fr/press/Agenus-To-Host-BOTBAL-Program-Update-at-ESMO-2023 https://www.agenusbio.com/es/press/Agenus-To-Host-BOTBAL-Program-Update-at-ESMO-2023 https://www.agenusbio.com/press/Agenus-To-Present-Data-on-Proprietary-CTLA-4-PD-1-Antibodies-at-ESMO-2018-10-09-2018 https://www.agenusbio.com/fr/press/Agenus-To-Present-Data-on-Proprietary-CTLA-4-PD-1-Antibodies-at-ESMO-2018-10-09-2018 https://www.agenusbio.com/es/press/Agenus-To-Present-Data-on-Proprietary-CTLA-4-PD-1-Antibodies-at-ESMO-2018-10-09-2018 https://www.agenusbio.com/press/Agenus-To-Present-on-Lead-Antibody-Programs-AGEN1884-CTLA-4-and-AGEN2034-PD-1-at-SITC-2017-11-09-2017 https://www.agenusbio.com/fr/press/Agenus-To-Present-on-Lead-Antibody-Programs-AGEN1884-CTLA-4-and-AGEN2034-PD-1-at-SITC-2017-11-09-2017 https://www.agenusbio.com/es/press/Agenus-To-Present-on-Lead-Antibody-Programs-AGEN1884-CTLA-4-and-AGEN2034-PD-1-at-SITC-2017-11-09-2017 https://www.agenusbio.com/press/Agenus-Triggers-3rd-Milestone-in-its-Collaboration-with-Gilead-08-28-2019 https://www.agenusbio.com/fr/press/Agenus-Triggers-3rd-Milestone-in-its-Collaboration-with-Gilead-08-28-2019 https://www.agenusbio.com/es/press/Agenus-Triggers-3rd-Milestone-in-its-Collaboration-with-Gilead-08-28-2019 https://www.agenusbio.com/press/Agenus-Unveils-Colorectal-Cancer-Survey-Findings-Highlighting-the-Urgent-Need-for-Treatment-Innovation https://www.agenusbio.com/fr/press/Agenus-Unveils-Colorectal-Cancer-Survey-Findings-Highlighting-the-Urgent-Need-for-Treatment-Innovation https://www.agenusbio.com/es/press/Agenus-Unveils-Colorectal-Cancer-Survey-Findings-Highlighting-the-Urgent-Need-for-Treatment-Innovation https://www.agenusbio.com/press/Agenus-Unveils-New-and-Updated-Botensilimab-Data-in-Colorectal-Pancreatic-Lung-Melanoma-and-Sarcoma https://www.agenusbio.com/fr/press/Agenus-Unveils-New-and-Updated-Botensilimab-Data-in-Colorectal-Pancreatic-Lung-Melanoma-and-Sarcoma https://www.agenusbio.com/es/press/Agenus-Unveils-New-and-Updated-Botensilimab-Data-in-Colorectal-Pancreatic-Lung-Melanoma-and-Sarcoma https://www.agenusbio.com/press/Agenus-Vaccine-Shows-Significant-Reduction-in-Viral-Burden-after-HerpV-Generated-Immune-Activation-06-26-2014 https://www.agenusbio.com/fr/press/Agenus-Vaccine-Shows-Significant-Reduction-in-Viral-Burden-after-HerpV-Generated-Immune-Activation-06-26-2014 https://www.agenusbio.com/es/press/Agenus-Vaccine-Shows-Significant-Reduction-in-Viral-Burden-after-HerpV-Generated-Immune-Activation-06-26-2014 https://www.agenusbio.com/press/Agenus-and-AgenTus-to-Participate-in-a-Panel-Presentation-on-Cell-Therapy-at-the-Raymond-James-Virtual-Human-Health-Innovation-Conference-06-17-2020 https://www.agenusbio.com/fr/press/Agenus-and-AgenTus-to-Participate-in-a-Panel-Presentation-on-Cell-Therapy-at-the-Raymond-James-Virtual-Human-Health-Innovation-Conference-06-17-2020 https://www.agenusbio.com/es/press/Agenus-and-AgenTus-to-Participate-in-a-Panel-Presentation-on-Cell-Therapy-at-the-Raymond-James-Virtual-Human-Health-Innovation-Conference-06-17-2020 https://www.agenusbio.com/press/Agenus-and-Betta-Pharmaceuticals-Enter-Into-a-License-Agreement-for-Balstilimab-and-Zalifrelimab-in-Greater-China-06-22-2020 https://www.agenusbio.com/fr/press/Agenus-and-Betta-Pharmaceuticals-Enter-Into-a-License-Agreement-for-Balstilimab-and-Zalifrelimab-in-Greater-China-06-22-2020 https://www.agenusbio.com/es/press/Agenus-and-Betta-Pharmaceuticals-Enter-Into-a-License-Agreement-for-Balstilimab-and-Zalifrelimab-in-Greater-China-06-22-2020 https://www.agenusbio.com/press/Agenus-and-Bristol-Myers-Squibb-Announce-Exclusive-Global-License-for-Agenus-Anti-TIGIT-Bispecific-Antibody-Program-05-18-2021 https://www.agenusbio.com/fr/press/Agenus-and-Bristol-Myers-Squibb-Announce-Exclusive-Global-License-for-Agenus-Anti-TIGIT-Bispecific-Antibody-Program-05-18-2021 https://www.agenusbio.com/es/press/Agenus-and-Bristol-Myers-Squibb-Announce-Exclusive-Global-License-for-Agenus-Anti-TIGIT-Bispecific-Antibody-Program-05-18-2021 https://www.agenusbio.com/press/Agenus-and-Noetik-Enter-Collaboration-to-Develop-AI-Enabled-Predictive-Biomarkers-for-BOTBAL-Using-Foundation-Models-of-Virtual-Cell-Biology-020d0 https://www.agenusbio.com/fr/press/Agenus-and-Noetik-Enter-Collaboration-to-Develop-AI-Enabled-Predictive-Biomarkers-for-BOTBAL-Using-Foundation-Models-of-Virtual-Cell-Biology-020d0 https://www.agenusbio.com/es/press/Agenus-and-Noetik-Enter-Collaboration-to-Develop-AI-Enabled-Predictive-Biomarkers-for-BOTBAL-Using-Foundation-Models-of-Virtual-Cell-Biology-020d0 https://www.agenusbio.com/press/Agenus-and-Vaxlogic-LLC-Execute-QS-21-Stimulon-Adjuvant-Licensing-Agreement-for-Addiction-Allergy-and-Respiratory-Vaccines-09-26-2013 https://www.agenusbio.com/fr/press/Agenus-and-Vaxlogic-LLC-Execute-QS-21-Stimulon-Adjuvant-Licensing-Agreement-for-Addiction-Allergy-and-Respiratory-Vaccines-09-26-2013 https://www.agenusbio.com/es/press/Agenus-and-Vaxlogic-LLC-Execute-QS-21-Stimulon-Adjuvant-Licensing-Agreement-for-Addiction-Allergy-and-Respiratory-Vaccines-09-26-2013 https://www.agenusbio.com/press/Agenus-and-Zydus-Lifesciences-Enter-141M-Strategic-Collaboration-to-Advance-BOTBAL-Expand-Zydus-Biologics-Manufacturing-in-the-US https://www.agenusbio.com/fr/press/Agenus-and-Zydus-Lifesciences-Enter-141M-Strategic-Collaboration-to-Advance-BOTBAL-Expand-Zydus-Biologics-Manufacturing-in-the-US https://www.agenusbio.com/es/press/Agenus-and-Zydus-Lifesciences-Enter-141M-Strategic-Collaboration-to-Advance-BOTBAL-Expand-Zydus-Biologics-Manufacturing-in-the-US https://www.agenusbio.com/press/Agenus-anti-CTLA-4-antibody-shows-strong-safety-and-tolerability-06-05-2017 https://www.agenusbio.com/fr/press/Agenus-anti-CTLA-4-antibody-shows-strong-safety-and-tolerability-06-05-2017 https://www.agenusbio.com/es/press/Agenus-anti-CTLA-4-antibody-shows-strong-safety-and-tolerability-06-05-2017 https://www.agenusbio.com/press/Agenus-creates-New-Cell-Therapy-subsidiary-named-AgenTus-Therapeutics-10-23-2017 https://www.agenusbio.com/fr/press/Agenus-creates-New-Cell-Therapy-subsidiary-named-AgenTus-Therapeutics-10-23-2017 https://www.agenusbio.com/es/press/Agenus-creates-New-Cell-Therapy-subsidiary-named-AgenTus-Therapeutics-10-23-2017 https://www.agenusbio.com/press/Agenus-receives-10M-from-UroGen-Pharma-for-rights-to-Zalifrelimab-CTLA-4-for-intravesical-treatment-of-urinary-tract-cancers-11-11-2019 https://www.agenusbio.com/fr/press/Agenus-receives-10M-from-UroGen-Pharma-for-rights-to-Zalifrelimab-CTLA-4-for-intravesical-treatment-of-urinary-tract-cancers-11-11-2019 https://www.agenusbio.com/es/press/Agenus-receives-10M-from-UroGen-Pharma-for-rights-to-Zalifrelimab-CTLA-4-for-intravesical-treatment-of-urinary-tract-cancers-11-11-2019 https://www.agenusbio.com/press/Agenus-to-Acquire-Antibody-Manufacturing-Capability-Expands-Antibody-Discovery-and-adds-Cell-Line-Development-Capabilities-with-Three-Separate-Transactions-11-05-2015 https://www.agenusbio.com/fr/press/Agenus-to-Acquire-Antibody-Manufacturing-Capability-Expands-Antibody-Discovery-and-adds-Cell-Line-Development-Capabilities-with-Three-Separate-Transactions-11-05-2015 https://www.agenusbio.com/es/press/Agenus-to-Acquire-Antibody-Manufacturing-Capability-Expands-Antibody-Discovery-and-adds-Cell-Line-Development-Capabilities-with-Three-Separate-Transactions-11-05-2015 https://www.agenusbio.com/press/Agenus-to-Highlight-Emerging-Survival-Plateaus-with-BotensilimabBalstilimab-in-Oral-Presentation-of-Study-in-Refractory-Patients-Across-Five-Tumor-Types-at-ESMO-2025-18aa7 https://www.agenusbio.com/fr/press/Agenus-to-Highlight-Emerging-Survival-Plateaus-with-BotensilimabBalstilimab-in-Oral-Presentation-of-Study-in-Refractory-Patients-Across-Five-Tumor-Types-at-ESMO-2025-18aa7 https://www.agenusbio.com/es/press/Agenus-to-Highlight-Emerging-Survival-Plateaus-with-BotensilimabBalstilimab-in-Oral-Presentation-of-Study-in-Refractory-Patients-Across-Five-Tumor-Types-at-ESMO-2025-18aa7 https://www.agenusbio.com/press/Agenus-to-Host-Annual-Meeting-of-Stockholders-04-16-2014 https://www.agenusbio.com/fr/press/Agenus-to-Host-Annual-Meeting-of-Stockholders-04-16-2014 https://www.agenusbio.com/es/press/Agenus-to-Host-Annual-Meeting-of-Stockholders-04-16-2014 https://www.agenusbio.com/press/Agenus-to-Host-Annual-Meeting-of-Stockholders-06-13-2019 https://www.agenusbio.com/fr/press/Agenus-to-Host-Annual-Meeting-of-Stockholders-06-13-2019 https://www.agenusbio.com/es/press/Agenus-to-Host-Annual-Meeting-of-Stockholders-06-13-2019 https://www.agenusbio.com/press/Agenus-to-Host-Call-to-Launch-First-Asset-Backed-Digital-Security-Offering-in-Healthcare-on-February-19-2019-02-15-2019 https://www.agenusbio.com/fr/press/Agenus-to-Host-Call-to-Launch-First-Asset-Backed-Digital-Security-Offering-in-Healthcare-on-February-19-2019-02-15-2019 https://www.agenusbio.com/es/press/Agenus-to-Host-Call-to-Launch-First-Asset-Backed-Digital-Security-Offering-in-Healthcare-on-February-19-2019-02-15-2019 https://www.agenusbio.com/press/Agenus-to-Host-Conference-Call-to-Discuss-Global-Licensing-Agreement-with-Bristol-Myers-Squibb-for-Agenus-Anti-TIGIT-Bispecific-Antibody-Program-05-18-2021 https://www.agenusbio.com/fr/press/Agenus-to-Host-Conference-Call-to-Discuss-Global-Licensing-Agreement-with-Bristol-Myers-Squibb-for-Agenus-Anti-TIGIT-Bispecific-Antibody-Program-05-18-2021 https://www.agenusbio.com/es/press/Agenus-to-Host-Conference-Call-to-Discuss-Global-Licensing-Agreement-with-Bristol-Myers-Squibb-for-Agenus-Anti-TIGIT-Bispecific-Antibody-Program-05-18-2021 https://www.agenusbio.com/press/Agenus-to-Host-End-of-Year-Stakeholder-Webcast-Featuring-GI-Oncology-Leaders-and-Progress-of-BOTBAL-349ef https://www.agenusbio.com/fr/press/Agenus-to-Host-End-of-Year-Stakeholder-Webcast-Featuring-GI-Oncology-Leaders-and-Progress-of-BOTBAL-349ef https://www.agenusbio.com/es/press/Agenus-to-Host-End-of-Year-Stakeholder-Webcast-Featuring-GI-Oncology-Leaders-and-Progress-of-BOTBAL-349ef https://www.agenusbio.com/press/Agenus-to-Host-First-2026-Stakeholder-Webcast-3e809 https://www.agenusbio.com/fr/press/Agenus-to-Host-First-2026-Stakeholder-Webcast-3e809 https://www.agenusbio.com/es/press/Agenus-to-Host-First-2026-Stakeholder-Webcast-3e809 https://www.agenusbio.com/press/Agenus-to-Host-Investor-Webcast-to-Review-Late-Breaking-Botensilimab-and-Balstilimab-Data-Presented-at-ESMO-World-GI-Congress-06-21-2022 https://www.agenusbio.com/fr/press/Agenus-to-Host-Investor-Webcast-to-Review-Late-Breaking-Botensilimab-and-Balstilimab-Data-Presented-at-ESMO-World-GI-Congress-06-21-2022 https://www.agenusbio.com/es/press/Agenus-to-Host-Investor-Webcast-to-Review-Late-Breaking-Botensilimab-and-Balstilimab-Data-Presented-at-ESMO-World-GI-Congress-06-21-2022 https://www.agenusbio.com/press/Agenus-to-Host-October-Stakeholder-Briefing-Showcasing-BOTBAL-Global-Momentum-and-Post-ESMO-Insights-217f0 https://www.agenusbio.com/fr/press/Agenus-to-Host-October-Stakeholder-Briefing-Showcasing-BOTBAL-Global-Momentum-and-Post-ESMO-Insights-217f0 https://www.agenusbio.com/es/press/Agenus-to-Host-October-Stakeholder-Briefing-Showcasing-BOTBAL-Global-Momentum-and-Post-ESMO-Insights-217f0 https://www.agenusbio.com/press/Agenus-to-Host-RD-Day-November-15-2019-11-12-2019 https://www.agenusbio.com/fr/press/Agenus-to-Host-RD-Day-November-15-2019-11-12-2019 https://www.agenusbio.com/es/press/Agenus-to-Host-RD-Day-November-15-2019-11-12-2019 https://www.agenusbio.com/press/Agenus-to-Host-Research-and-Development-Day-on-May-14-2015-05-08-2015 https://www.agenusbio.com/fr/press/Agenus-to-Host-Research-and-Development-Day-on-May-14-2015-05-08-2015 https://www.agenusbio.com/es/press/Agenus-to-Host-Research-and-Development-Day-on-May-14-2015-05-08-2015 https://www.agenusbio.com/press/Agenus-to-Host-The-Road-Taken-RD-Event-on-November-12-2022-10-05-2022 https://www.agenusbio.com/fr/press/Agenus-to-Host-The-Road-Taken-RD-Event-on-November-12-2022-10-05-2022 https://www.agenusbio.com/es/press/Agenus-to-Host-The-Road-Taken-RD-Event-on-November-12-2022-10-05-2022 https://www.agenusbio.com/press/Agenus-to-Launch-the-First-Asset-Backed-Digital-Security-Offering-in-Healthcare-01-29-2019 https://www.agenusbio.com/fr/press/Agenus-to-Launch-the-First-Asset-Backed-Digital-Security-Offering-in-Healthcare-01-29-2019 https://www.agenusbio.com/es/press/Agenus-to-Launch-the-First-Asset-Backed-Digital-Security-Offering-in-Healthcare-01-29-2019 https://www.agenusbio.com/press/Agenus-to-Manufacture-Clinical-Supply-of-GS-1423-for-Gilead-08-21-2019 https://www.agenusbio.com/fr/press/Agenus-to-Manufacture-Clinical-Supply-of-GS-1423-for-Gilead-08-21-2019 https://www.agenusbio.com/es/press/Agenus-to-Manufacture-Clinical-Supply-of-GS-1423-for-Gilead-08-21-2019 https://www.agenusbio.com/press/Agenus-to-Participate-at-5th-Annual-Evercore-ISI-HealthCONx-Conference-11-16-2022 https://www.agenusbio.com/fr/press/Agenus-to-Participate-at-5th-Annual-Evercore-ISI-HealthCONx-Conference-11-16-2022 https://www.agenusbio.com/es/press/Agenus-to-Participate-at-5th-Annual-Evercore-ISI-HealthCONx-Conference-11-16-2022 https://www.agenusbio.com/press/Agenus-to-Participate-at-B-Riley-Securities-2023-Virtual-Oncology-Conference-01-10-2023 https://www.agenusbio.com/fr/press/Agenus-to-Participate-at-B-Riley-Securities-2023-Virtual-Oncology-Conference-01-10-2023 https://www.agenusbio.com/es/press/Agenus-to-Participate-at-B-Riley-Securities-2023-Virtual-Oncology-Conference-01-10-2023 https://www.agenusbio.com/press/Agenus-to-Participate-at-BTIG-Biotechnology-Conference-08-02-2022 https://www.agenusbio.com/fr/press/Agenus-to-Participate-at-BTIG-Biotechnology-Conference-08-02-2022 https://www.agenusbio.com/es/press/Agenus-to-Participate-at-BTIG-Biotechnology-Conference-08-02-2022 https://www.agenusbio.com/press/Agenus-to-Participate-at-Jefferies-Healthcare-Conference-05-25-2022 https://www.agenusbio.com/fr/press/Agenus-to-Participate-at-Jefferies-Healthcare-Conference-05-25-2022 https://www.agenusbio.com/es/press/Agenus-to-Participate-at-Jefferies-Healthcare-Conference-05-25-2022 https://www.agenusbio.com/press/Agenus-to-Participate-at-Three-Upcoming-Oncology-Conferences-03-30-2016 https://www.agenusbio.com/fr/press/Agenus-to-Participate-at-Three-Upcoming-Oncology-Conferences-03-30-2016 https://www.agenusbio.com/es/press/Agenus-to-Participate-at-Three-Upcoming-Oncology-Conferences-03-30-2016 https://www.agenusbio.com/press/Agenus-to-Participate-at-Two-Upcoming-Conferences-in-New-York-City-Jefferies-Healthcare-and-JMP-Securities-Life-Sciences-06-01-2017 https://www.agenusbio.com/fr/press/Agenus-to-Participate-at-Two-Upcoming-Conferences-in-New-York-City-Jefferies-Healthcare-and-JMP-Securities-Life-Sciences-06-01-2017 https://www.agenusbio.com/es/press/Agenus-to-Participate-at-Two-Upcoming-Conferences-in-New-York-City-Jefferies-Healthcare-and-JMP-Securities-Life-Sciences-06-01-2017 https://www.agenusbio.com/press/Agenus-to-Participate-at-Two-Upcoming-Immuno-Oncology-Conferences-03-24-2017 https://www.agenusbio.com/fr/press/Agenus-to-Participate-at-Two-Upcoming-Immuno-Oncology-Conferences-03-24-2017 https://www.agenusbio.com/es/press/Agenus-to-Participate-at-Two-Upcoming-Immuno-Oncology-Conferences-03-24-2017 https://www.agenusbio.com/press/Agenus-to-Participate-at-Upcoming-Investor-Conferences-01-05-2022 https://www.agenusbio.com/fr/press/Agenus-to-Participate-at-Upcoming-Investor-Conferences-01-05-2022 https://www.agenusbio.com/es/press/Agenus-to-Participate-at-Upcoming-Investor-Conferences-01-05-2022 https://www.agenusbio.com/press/Agenus-to-Participate-at-William-Blairs-Biotech-Focus-Conference-06-30-2022 https://www.agenusbio.com/fr/press/Agenus-to-Participate-at-William-Blairs-Biotech-Focus-Conference-06-30-2022 https://www.agenusbio.com/es/press/Agenus-to-Participate-at-William-Blairs-Biotech-Focus-Conference-06-30-2022 https://www.agenusbio.com/press/Agenus-to-Participate-in-4th-Annual-Evercore-ISI-HealthCONx-Conference-11-17-2021 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-4th-Annual-Evercore-ISI-HealthCONx-Conference-11-17-2021 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-4th-Annual-Evercore-ISI-HealthCONx-Conference-11-17-2021 https://www.agenusbio.com/press/Agenus-to-Participate-in-Brain-Cancer-Vaccine-and-Immunotherapy-Discussion-on-September-23rd-Webcast-09-18-2013 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Brain-Cancer-Vaccine-and-Immunotherapy-Discussion-on-September-23rd-Webcast-09-18-2013 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Brain-Cancer-Vaccine-and-Immunotherapy-Discussion-on-September-23rd-Webcast-09-18-2013 https://www.agenusbio.com/press/Agenus-to-Participate-in-Evercore-ISI-3rd-Annual-HealthCONx-Conference-11-25-2020 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Evercore-ISI-3rd-Annual-HealthCONx-Conference-11-25-2020 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Evercore-ISI-3rd-Annual-HealthCONx-Conference-11-25-2020 https://www.agenusbio.com/press/Agenus-to-Participate-in-February-Investor-Conferences-01-26-2023 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-February-Investor-Conferences-01-26-2023 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-February-Investor-Conferences-01-26-2023 https://www.agenusbio.com/press/Agenus-to-Participate-in-Fireside-Chat-at-the-Jefferies-2020-Virtual-London-Healthcare-Conference-11-16-2020 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Fireside-Chat-at-the-Jefferies-2020-Virtual-London-Healthcare-Conference-11-16-2020 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Fireside-Chat-at-the-Jefferies-2020-Virtual-London-Healthcare-Conference-11-16-2020 https://www.agenusbio.com/press/Agenus-to-Participate-in-Fireside-Chat-at-the-Jefferies-2021-Virtual-Healthcare-Conference-06-01-2021 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Fireside-Chat-at-the-Jefferies-2021-Virtual-Healthcare-Conference-06-01-2021 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Fireside-Chat-at-the-Jefferies-2021-Virtual-Healthcare-Conference-06-01-2021 https://www.agenusbio.com/press/Agenus-to-Participate-in-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference https://www.agenusbio.com/press/Agenus-to-Participate-in-Jefferies-Healthcare-Conference-05-25-2023 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Jefferies-Healthcare-Conference-05-25-2023 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Jefferies-Healthcare-Conference-05-25-2023 https://www.agenusbio.com/press/Agenus-to-Participate-in-Leerink-Partners-Global-Biopharma-Conference https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Leerink-Partners-Global-Biopharma-Conference https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Leerink-Partners-Global-Biopharma-Conference https://www.agenusbio.com/press/Agenus-to-Participate-in-May-Investor-Conferences-04-24-2023 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-May-Investor-Conferences-04-24-2023 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-May-Investor-Conferences-04-24-2023 https://www.agenusbio.com/press/Agenus-to-Participate-in-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference https://www.agenusbio.com/press/Agenus-to-Participate-in-Resistance-Focused-Oncology-Panel-at-the-William-Blair-Biotech-Focus-Conference-2021-07-07-2021 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Resistance-Focused-Oncology-Panel-at-the-William-Blair-Biotech-Focus-Conference-2021-07-07-2021 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Resistance-Focused-Oncology-Panel-at-the-William-Blair-Biotech-Focus-Conference-2021-07-07-2021 https://www.agenusbio.com/press/Agenus-to-Participate-in-September-Investor-Conferences https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-September-Investor-Conferences https://www.agenusbio.com/es/press/Agenus-to-Participate-in-September-Investor-Conferences https://www.agenusbio.com/press/Agenus-to-Participate-in-Two-Upcoming-Investor-Conferences-09-02-2014 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Two-Upcoming-Investor-Conferences-09-02-2014 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Two-Upcoming-Investor-Conferences-09-02-2014 https://www.agenusbio.com/press/Agenus-to-Participate-in-Webcast-Hosted-by-William-Blair-on-AGEN1181-and-Balstilimab-AACR-Presentations-04-06-2021 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Webcast-Hosted-by-William-Blair-on-AGEN1181-and-Balstilimab-AACR-Presentations-04-06-2021 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Webcast-Hosted-by-William-Blair-on-AGEN1181-and-Balstilimab-AACR-Presentations-04-06-2021 https://www.agenusbio.com/press/Agenus-to-Participate-in-Webcast-Hosted-by-William-Blair-on-ESMO2020-Results-and-Novel-Pipeline-09-17-2020 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Webcast-Hosted-by-William-Blair-on-ESMO2020-Results-and-Novel-Pipeline-09-17-2020 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Webcast-Hosted-by-William-Blair-on-ESMO2020-Results-and-Novel-Pipeline-09-17-2020 https://www.agenusbio.com/press/Agenus-to-Participate-in-Webcast-Hosted-by-William-Blair-to-Discuss-AGEN1181-Clinical-Data-from-SITC-2021-Meeting-11-04-2021 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-Webcast-Hosted-by-William-Blair-to-Discuss-AGEN1181-Clinical-Data-from-SITC-2021-Meeting-11-04-2021 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-Webcast-Hosted-by-William-Blair-to-Discuss-AGEN1181-Clinical-Data-from-SITC-2021-Meeting-11-04-2021 https://www.agenusbio.com/press/Agenus-to-Participate-in-the-BTIG-Virtual-Biotechnology-Conference-2021-08-02-2021 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-the-BTIG-Virtual-Biotechnology-Conference-2021-08-02-2021 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-the-BTIG-Virtual-Biotechnology-Conference-2021-08-02-2021 https://www.agenusbio.com/press/Agenus-to-Participate-in-the-H-C--Wainwright-27th-Annual-Global-Investment-Conference-8350a https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-the-H-C--Wainwright-27th-Annual-Global-Investment-Conference-8350a https://www.agenusbio.com/es/press/Agenus-to-Participate-in-the-H-C--Wainwright-27th-Annual-Global-Investment-Conference-8350a https://www.agenusbio.com/press/Agenus-to-Participate-in-the-Raymond-James-2021-Human-Health-Innovation-Conference-06-21-2021 https://www.agenusbio.com/fr/press/Agenus-to-Participate-in-the-Raymond-James-2021-Human-Health-Innovation-Conference-06-21-2021 https://www.agenusbio.com/es/press/Agenus-to-Participate-in-the-Raymond-James-2021-Human-Health-Innovation-Conference-06-21-2021 https://www.agenusbio.com/press/Agenus-to-Present-AGEN1181-Clinical-Data-at-SITC-10-01-2021 https://www.agenusbio.com/fr/press/Agenus-to-Present-AGEN1181-Clinical-Data-at-SITC-10-01-2021 https://www.agenusbio.com/es/press/Agenus-to-Present-AGEN1181-Clinical-Data-at-SITC-10-01-2021 https://www.agenusbio.com/press/Agenus-to-Present-Botensilimab-Data-at-Late-Breaking-Oral-Session-at-ASCO-GI-12-21-2022 https://www.agenusbio.com/fr/press/Agenus-to-Present-Botensilimab-Data-at-Late-Breaking-Oral-Session-at-ASCO-GI-12-21-2022 https://www.agenusbio.com/es/press/Agenus-to-Present-Botensilimab-Data-at-Late-Breaking-Oral-Session-at-ASCO-GI-12-21-2022 https://www.agenusbio.com/press/Agenus-to-Present-Botensilimab-Data-at-a-Plenary-Session-of-the-Society-for-Immunotherapy-of-Cancer-SITC-37th-Annual-Meeting-10-05-2022 https://www.agenusbio.com/fr/press/Agenus-to-Present-Botensilimab-Data-at-a-Plenary-Session-of-the-Society-for-Immunotherapy-of-Cancer-SITC-37th-Annual-Meeting-10-05-2022 https://www.agenusbio.com/es/press/Agenus-to-Present-Botensilimab-Data-at-a-Plenary-Session-of-the-Society-for-Immunotherapy-of-Cancer-SITC-37th-Annual-Meeting-10-05-2022 https://www.agenusbio.com/press/Agenus-to-Present-Botensilimab-Data-in-Oral-Plenary-Session-at-the-Society-of-Gynecologic-Oncology-2023-Annual-Meeting-on-Womens-Cancer-02-28-2023 https://www.agenusbio.com/fr/press/Agenus-to-Present-Botensilimab-Data-in-Oral-Plenary-Session-at-the-Society-of-Gynecologic-Oncology-2023-Annual-Meeting-on-Womens-Cancer-02-28-2023 https://www.agenusbio.com/es/press/Agenus-to-Present-Botensilimab-Data-in-Oral-Plenary-Session-at-the-Society-of-Gynecologic-Oncology-2023-Annual-Meeting-on-Womens-Cancer-02-28-2023 https://www.agenusbio.com/press/Agenus-to-Present-Clinical-Data-on-Lead-Programs-at-ASCO-2018-05-17-2018 https://www.agenusbio.com/fr/press/Agenus-to-Present-Clinical-Data-on-Lead-Programs-at-ASCO-2018-05-17-2018 https://www.agenusbio.com/es/press/Agenus-to-Present-Clinical-Data-on-Lead-Programs-at-ASCO-2018-05-17-2018 https://www.agenusbio.com/press/Agenus-to-Present-Compelling-Data-on-Botensilimab-and-AGEN1721-at-SITC-2024 https://www.agenusbio.com/fr/press/Agenus-to-Present-Compelling-Data-on-Botensilimab-and-AGEN1721-at-SITC-2024 https://www.agenusbio.com/es/press/Agenus-to-Present-Compelling-Data-on-Botensilimab-and-AGEN1721-at-SITC-2024 https://www.agenusbio.com/press/Agenus-to-Present-Data-on-Neoantigen-Vaccines-and-anti-CD137-Antibody-at-SITC-2018-11-06-2018 https://www.agenusbio.com/fr/press/Agenus-to-Present-Data-on-Neoantigen-Vaccines-and-anti-CD137-Antibody-at-SITC-2018-11-06-2018 https://www.agenusbio.com/es/press/Agenus-to-Present-Data-on-Neoantigen-Vaccines-and-anti-CD137-Antibody-at-SITC-2018-11-06-2018 https://www.agenusbio.com/press/Agenus-to-Present-New-BOTBAL-Data-in-Two-Presentations-at-AACR-2025 https://www.agenusbio.com/fr/press/Agenus-to-Present-New-BOTBAL-Data-in-Two-Presentations-at-AACR-2025 https://www.agenusbio.com/es/press/Agenus-to-Present-New-BOTBAL-Data-in-Two-Presentations-at-AACR-2025 https://www.agenusbio.com/press/Agenus-to-Present-New-Clinical-Data-on-AGEN1181-at-AACR-2021-03-10-2021 https://www.agenusbio.com/fr/press/Agenus-to-Present-New-Clinical-Data-on-AGEN1181-at-AACR-2021-03-10-2021 https://www.agenusbio.com/es/press/Agenus-to-Present-New-Clinical-Data-on-AGEN1181-at-AACR-2021-03-10-2021 https://www.agenusbio.com/press/Agenus-to-Present-at-BIO-CEO-Investor-Conference-02-06-2014 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-BIO-CEO-Investor-Conference-02-06-2014 https://www.agenusbio.com/es/press/Agenus-to-Present-at-BIO-CEO-Investor-Conference-02-06-2014 https://www.agenusbio.com/press/Agenus-to-Present-at-Cambridge-Healthtech-Institutes-Second-Annual-Conference-on-Immunomodulatory-Therapeutic-Antibodies-for-Cancer-08-04-2014 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-Cambridge-Healthtech-Institutes-Second-Annual-Conference-on-Immunomodulatory-Therapeutic-Antibodies-for-Cancer-08-04-2014 https://www.agenusbio.com/es/press/Agenus-to-Present-at-Cambridge-Healthtech-Institutes-Second-Annual-Conference-on-Immunomodulatory-Therapeutic-Antibodies-for-Cancer-08-04-2014 https://www.agenusbio.com/press/Agenus-to-Present-at-Deutsche-Banks-43rd-Annual-Health-Care-Conference-in-Boston-05-07-2018 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-Deutsche-Banks-43rd-Annual-Health-Care-Conference-in-Boston-05-07-2018 https://www.agenusbio.com/es/press/Agenus-to-Present-at-Deutsche-Banks-43rd-Annual-Health-Care-Conference-in-Boston-05-07-2018 https://www.agenusbio.com/press/Agenus-to-Present-at-Healthcare-Investor-Conferences-In-April-03-29-2018 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-Healthcare-Investor-Conferences-In-April-03-29-2018 https://www.agenusbio.com/es/press/Agenus-to-Present-at-Healthcare-Investor-Conferences-In-April-03-29-2018 https://www.agenusbio.com/press/Agenus-to-Present-at-Jefferies-2014-Global-Healthcare-Conference-05-30-2014 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-Jefferies-2014-Global-Healthcare-Conference-05-30-2014 https://www.agenusbio.com/es/press/Agenus-to-Present-at-Jefferies-2014-Global-Healthcare-Conference-05-30-2014 https://www.agenusbio.com/press/Agenus-to-Present-at-Two-Healthcare-Investor-Conferences-In-September-09-19-2017 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-Two-Healthcare-Investor-Conferences-In-September-09-19-2017 https://www.agenusbio.com/es/press/Agenus-to-Present-at-Two-Healthcare-Investor-Conferences-In-September-09-19-2017 https://www.agenusbio.com/press/Agenus-to-Present-at-the-17th-Annual-BIO-CEO-Investor-Conference-02-03-2015 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-17th-Annual-BIO-CEO-Investor-Conference-02-03-2015 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-17th-Annual-BIO-CEO-Investor-Conference-02-03-2015 https://www.agenusbio.com/press/Agenus-to-Present-at-the-2015-JMP-Securities-Life-Sciences-Conference-06-18-2015 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-2015-JMP-Securities-Life-Sciences-Conference-06-18-2015 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-2015-JMP-Securities-Life-Sciences-Conference-06-18-2015 https://www.agenusbio.com/press/Agenus-to-Present-at-the-2016-JMP-Securities-Life-Sciences-Conference-06-15-2016 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-2016-JMP-Securities-Life-Sciences-Conference-06-15-2016 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-2016-JMP-Securities-Life-Sciences-Conference-06-15-2016 https://www.agenusbio.com/press/Agenus-to-Present-at-the-2018-Cantor-Fitzgerald-Global-Healthcare-Conference-in-New-York-NY-09-28-2018 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-2018-Cantor-Fitzgerald-Global-Healthcare-Conference-in-New-York-NY-09-28-2018 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-2018-Cantor-Fitzgerald-Global-Healthcare-Conference-in-New-York-NY-09-28-2018 https://www.agenusbio.com/press/Agenus-to-Present-at-the-2018-Jefferies-London-Healthcare-Conference-11-13-2018 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-2018-Jefferies-London-Healthcare-Conference-11-13-2018 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-2018-Jefferies-London-Healthcare-Conference-11-13-2018 https://www.agenusbio.com/press/Agenus-to-Present-at-the-2019-Cantor-Global-Healthcare-Conference-on-October-4-2019-09-30-2019 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-2019-Cantor-Global-Healthcare-Conference-on-October-4-2019-09-30-2019 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-2019-Cantor-Global-Healthcare-Conference-on-October-4-2019-09-30-2019 https://www.agenusbio.com/press/Agenus-to-Present-at-the-2021-ASCO-Annual-Meeting-04-28-2021 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-2021-ASCO-Annual-Meeting-04-28-2021 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-2021-ASCO-Annual-Meeting-04-28-2021 https://www.agenusbio.com/press/Agenus-to-Present-at-the-4th-Annual-Cancer-Immunotherapy-Conference-03-26-2014 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-4th-Annual-Cancer-Immunotherapy-Conference-03-26-2014 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-4th-Annual-Cancer-Immunotherapy-Conference-03-26-2014 https://www.agenusbio.com/press/Agenus-to-Present-at-the-American-Society-of-Clinical-Oncology-2023-Annual-Meeting-04-26-2023 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-American-Society-of-Clinical-Oncology-2023-Annual-Meeting-04-26-2023 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-American-Society-of-Clinical-Oncology-2023-Annual-Meeting-04-26-2023 https://www.agenusbio.com/press/Agenus-to-Present-at-the-Cowen-and-Company-35th-Annual-Health-Care-Conference-02-25-2015 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-Cowen-and-Company-35th-Annual-Health-Care-Conference-02-25-2015 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-Cowen-and-Company-35th-Annual-Health-Care-Conference-02-25-2015 https://www.agenusbio.com/press/Agenus-to-Present-at-the-Cowen-and-Company-36th-Annual-Health-Care-Conference-03-01-2016 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-Cowen-and-Company-36th-Annual-Health-Care-Conference-03-01-2016 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-Cowen-and-Company-36th-Annual-Health-Care-Conference-03-01-2016 https://www.agenusbio.com/press/Agenus-to-Present-at-the-JMP-Securities-Annual-Healthcare-Conference-07-02-2013 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-JMP-Securities-Annual-Healthcare-Conference-07-02-2013 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-JMP-Securities-Annual-Healthcare-Conference-07-02-2013 https://www.agenusbio.com/press/Agenus-to-Present-at-the-JMP-Securities-Healthcare-Conference-06-19-2014 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-JMP-Securities-Healthcare-Conference-06-19-2014 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-JMP-Securities-Healthcare-Conference-06-19-2014 https://www.agenusbio.com/press/Agenus-to-Present-at-the-Jefferies-2015-Healthcare-Conference-05-28-2015 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-Jefferies-2015-Healthcare-Conference-05-28-2015 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-Jefferies-2015-Healthcare-Conference-05-28-2015 https://www.agenusbio.com/press/Agenus-to-Present-at-the-Jefferies-2016-Healthcare-Conference-06-02-2016 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-Jefferies-2016-Healthcare-Conference-06-02-2016 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-Jefferies-2016-Healthcare-Conference-06-02-2016 https://www.agenusbio.com/press/Agenus-to-Present-at-the-Jefferies-2016-London-Healthcare-Conference-11-14-2016 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-Jefferies-2016-London-Healthcare-Conference-11-14-2016 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-Jefferies-2016-London-Healthcare-Conference-11-14-2016 https://www.agenusbio.com/press/Agenus-to-Present-at-the-Jefferies-2018-Global-Healthcare-Conference-in-New-York-NY-06-06-2018 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-Jefferies-2018-Global-Healthcare-Conference-in-New-York-NY-06-06-2018 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-Jefferies-2018-Global-Healthcare-Conference-in-New-York-NY-06-06-2018 https://www.agenusbio.com/press/Agenus-to-Present-at-the-Jefferies-Global-Healthcare-Conference-in-London-11-08-2017 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-Jefferies-Global-Healthcare-Conference-in-London-11-08-2017 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-Jefferies-Global-Healthcare-Conference-in-London-11-08-2017 https://www.agenusbio.com/press/Agenus-to-Present-at-the-Oppenheimer-26th-Annual-Healthcare-Conference-12-01-2015 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-Oppenheimer-26th-Annual-Healthcare-Conference-12-01-2015 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-Oppenheimer-26th-Annual-Healthcare-Conference-12-01-2015 https://www.agenusbio.com/press/Agenus-to-Present-at-the-Raymond-James-Virtual-Human-Health-Innovation-Conference-06-17-2020 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-Raymond-James-Virtual-Human-Health-Innovation-Conference-06-17-2020 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-Raymond-James-Virtual-Human-Health-Innovation-Conference-06-17-2020 https://www.agenusbio.com/press/Agenus-to-Present-at-the-Rodman-Renshaw-17th-Annual-Global-Investment-Conference-09-08-2015 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-Rodman-Renshaw-17th-Annual-Global-Investment-Conference-09-08-2015 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-Rodman-Renshaw-17th-Annual-Global-Investment-Conference-09-08-2015 https://www.agenusbio.com/press/Agenus-to-Present-at-the-Rodman-Renshaw-18th-Annual-Global-Investment-Conference-09-06-2016 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-the-Rodman-Renshaw-18th-Annual-Global-Investment-Conference-09-06-2016 https://www.agenusbio.com/es/press/Agenus-to-Present-at-the-Rodman-Renshaw-18th-Annual-Global-Investment-Conference-09-06-2016 https://www.agenusbio.com/press/Agenus-to-Present-at-two-Upcoming-Healthcare-Conferences-Upcoming-Healthcare-Conferences-09-04-2013 https://www.agenusbio.com/fr/press/Agenus-to-Present-at-two-Upcoming-Healthcare-Conferences-Upcoming-Healthcare-Conferences-09-04-2013 https://www.agenusbio.com/es/press/Agenus-to-Present-at-two-Upcoming-Healthcare-Conferences-Upcoming-Healthcare-Conferences-09-04-2013 https://www.agenusbio.com/press/Agenus-to-Present-on-Seven-Novel-Programs-at-SITC-2020-10-14-2020 https://www.agenusbio.com/fr/press/Agenus-to-Present-on-Seven-Novel-Programs-at-SITC-2020-10-14-2020 https://www.agenusbio.com/es/press/Agenus-to-Present-on-Seven-Novel-Programs-at-SITC-2020-10-14-2020 https://www.agenusbio.com/press/Agenus-to-Present-on-Targeting-Myeloid-Cells-in-Tumor-Microenvironment-at-the-William-Blair-Biotech-Focus-2020-Conference-08-04-2020 https://www.agenusbio.com/fr/press/Agenus-to-Present-on-Targeting-Myeloid-Cells-in-Tumor-Microenvironment-at-the-William-Blair-Biotech-Focus-2020-Conference-08-04-2020 https://www.agenusbio.com/es/press/Agenus-to-Present-on-Targeting-Myeloid-Cells-in-Tumor-Microenvironment-at-the-William-Blair-Biotech-Focus-2020-Conference-08-04-2020 https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2021-Financial-Report-04-22-2021 https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2021-Financial-Report-04-22-2021 https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2021-Financial-Report-04-22-2021 https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2022-Financial-Report-04-26-2022 https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2022-Financial-Report-04-26-2022 https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2022-Financial-Report-04-26-2022 https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2023-Financial-Report-04-25-2023 https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2023-Financial-Report-04-25-2023 https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2023-Financial-Report-04-25-2023 https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2025-Financial-Report https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2025-Financial-Report https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-First-Quarter-2025-Financial-Report https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter--Full-Year-2023-Financial-Report https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter--Full-Year-2023-Financial-Report https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter--Full-Year-2023-Financial-Report https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter--Full-Year-2024-Financial-Report https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter--Full-Year-2024-Financial-Report https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter--Full-Year-2024-Financial-Report https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter-Full-Year-2020-Financial-Report-03-02-2021 https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter-Full-Year-2020-Financial-Report-03-02-2021 https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter-Full-Year-2020-Financial-Report-03-02-2021 https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter-Full-Year-2021-Financial-Report-02-15-2022 https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter-Full-Year-2021-Financial-Report-02-15-2022 https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter-Full-Year-2021-Financial-Report-02-15-2022 https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter-Full-Year-2022-Financial-Report-02-28-2023 https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter-Full-Year-2022-Financial-Report-02-28-2023 https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-Fourth-Quarter-Full-Year-2022-Financial-Report-02-28-2023 https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-Second-Quarter-2021-Financial-Report-07-26-2021 https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-Second-Quarter-2021-Financial-Report-07-26-2021 https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-Second-Quarter-2021-Financial-Report-07-26-2021 https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-Second-Quarter-2022-Financial-Report-07-27-2022 https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-Second-Quarter-2022-Financial-Report-07-27-2022 https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-Second-Quarter-2022-Financial-Report-07-27-2022 https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-Second-Quarter-2025-Financial-Report-c374d https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-Second-Quarter-2025-Financial-Report-c374d https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-Second-Quarter-2025-Financial-Report-c374d https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-Third-Quarter-2021-Financial-Report-10-25-2021 https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-Third-Quarter-2021-Financial-Report-10-25-2021 https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-Third-Quarter-2021-Financial-Report-10-25-2021 https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-Third-Quarter-2022-Financial-Report-10-25-2022 https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-Third-Quarter-2022-Financial-Report-10-25-2022 https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-Third-Quarter-2022-Financial-Report-10-25-2022 https://www.agenusbio.com/press/Agenus-to-Provide-Corporate-Update-and-Third-Quarter-2025-Financial-Report-76bfc https://www.agenusbio.com/fr/press/Agenus-to-Provide-Corporate-Update-and-Third-Quarter-2025-Financial-Report-76bfc https://www.agenusbio.com/es/press/Agenus-to-Provide-Corporate-Update-and-Third-Quarter-2025-Financial-Report-76bfc https://www.agenusbio.com/press/Agenus-to-Provide-First-Quarter-2024-Financial-Report-and-Corporate-Update https://www.agenusbio.com/fr/press/Agenus-to-Provide-First-Quarter-2024-Financial-Report-and-Corporate-Update https://www.agenusbio.com/es/press/Agenus-to-Provide-First-Quarter-2024-Financial-Report-and-Corporate-Update https://www.agenusbio.com/press/Agenus-to-Provide-Second-Quarter-2023-Financial-Report-and-Corporate-Update-07-26-2023 https://www.agenusbio.com/fr/press/Agenus-to-Provide-Second-Quarter-2023-Financial-Report-and-Corporate-Update-07-26-2023 https://www.agenusbio.com/es/press/Agenus-to-Provide-Second-Quarter-2023-Financial-Report-and-Corporate-Update-07-26-2023 https://www.agenusbio.com/press/Agenus-to-Provide-Second-Quarter-2024-Financial-Report-and-Corporate-Update https://www.agenusbio.com/fr/press/Agenus-to-Provide-Second-Quarter-2024-Financial-Report-and-Corporate-Update https://www.agenusbio.com/es/press/Agenus-to-Provide-Second-Quarter-2024-Financial-Report-and-Corporate-Update https://www.agenusbio.com/press/Agenus-to-Provide-Third-Quarter-2023-Financial-Report-and-Corporate-Update https://www.agenusbio.com/fr/press/Agenus-to-Provide-Third-Quarter-2023-Financial-Report-and-Corporate-Update https://www.agenusbio.com/es/press/Agenus-to-Provide-Third-Quarter-2023-Financial-Report-and-Corporate-Update https://www.agenusbio.com/press/Agenus-to-Provide-Third-Quarter-2024-Financial-Report-and-Corporate-Update https://www.agenusbio.com/fr/press/Agenus-to-Provide-Third-Quarter-2024-Financial-Report-and-Corporate-Update https://www.agenusbio.com/es/press/Agenus-to-Provide-Third-Quarter-2024-Financial-Report-and-Corporate-Update https://www.agenusbio.com/press/Agenus-to-Receive-20M-Milestone-Payment-from-Bristol-Myers-Squibb-with-Dosing-of-First-Patient-with-its-TIGIT-Bispecific-Antibody-10-12-2021 https://www.agenusbio.com/fr/press/Agenus-to-Receive-20M-Milestone-Payment-from-Bristol-Myers-Squibb-with-Dosing-of-First-Patient-with-its-TIGIT-Bispecific-Antibody-10-12-2021 https://www.agenusbio.com/es/press/Agenus-to-Receive-20M-Milestone-Payment-from-Bristol-Myers-Squibb-with-Dosing-of-First-Patient-with-its-TIGIT-Bispecific-Antibody-10-12-2021 https://www.agenusbio.com/press/Agenus-to-Receive-25-Million-Milestone-Payment-from-Bristol-Myers-Squibb-for-TIGIT-CD96-Bispecific-Program https://www.agenusbio.com/fr/press/Agenus-to-Receive-25-Million-Milestone-Payment-from-Bristol-Myers-Squibb-for-TIGIT-CD96-Bispecific-Program https://www.agenusbio.com/es/press/Agenus-to-Receive-25-Million-Milestone-Payment-from-Bristol-Myers-Squibb-for-TIGIT-CD96-Bispecific-Program https://www.agenusbio.com/press/Agenus-to-Report-First-Quarter-2013-Financial-Results-on-April-24-2013-Conference-Call-to-Follow-04-18-2013 https://www.agenusbio.com/fr/press/Agenus-to-Report-First-Quarter-2013-Financial-Results-on-April-24-2013-Conference-Call-to-Follow-04-18-2013 https://www.agenusbio.com/es/press/Agenus-to-Report-First-Quarter-2013-Financial-Results-on-April-24-2013-Conference-Call-to-Follow-04-18-2013 https://www.agenusbio.com/press/Agenus-to-Report-First-Quarter-2014-Financial-Results-on-May-8-2014-Conference-Call-to-Follow-04-29-2014 https://www.agenusbio.com/fr/press/Agenus-to-Report-First-Quarter-2014-Financial-Results-on-May-8-2014-Conference-Call-to-Follow-04-29-2014 https://www.agenusbio.com/es/press/Agenus-to-Report-First-Quarter-2014-Financial-Results-on-May-8-2014-Conference-Call-to-Follow-04-29-2014 https://www.agenusbio.com/press/Agenus-to-Report-First-Quarter-2015-Financial-Results-on-April-23-2015-Conference-Call-to-Follow-04-20-2015 https://www.agenusbio.com/fr/press/Agenus-to-Report-First-Quarter-2015-Financial-Results-on-April-23-2015-Conference-Call-to-Follow-04-20-2015 https://www.agenusbio.com/es/press/Agenus-to-Report-First-Quarter-2015-Financial-Results-on-April-23-2015-Conference-Call-to-Follow-04-20-2015 https://www.agenusbio.com/press/Agenus-to-Report-First-Quarter-2016-Financial-Results-on-April-28-2016-Conference-Call-to-Follow-04-21-2016 https://www.agenusbio.com/fr/press/Agenus-to-Report-First-Quarter-2016-Financial-Results-on-April-28-2016-Conference-Call-to-Follow-04-21-2016 https://www.agenusbio.com/es/press/Agenus-to-Report-First-Quarter-2016-Financial-Results-on-April-28-2016-Conference-Call-to-Follow-04-21-2016 https://www.agenusbio.com/press/Agenus-to-Report-First-Quarter-2017-Financial-Results-on-May-4-2017-Conference-Call-to-Follow-04-27-2017 https://www.agenusbio.com/fr/press/Agenus-to-Report-First-Quarter-2017-Financial-Results-on-May-4-2017-Conference-Call-to-Follow-04-27-2017 https://www.agenusbio.com/es/press/Agenus-to-Report-First-Quarter-2017-Financial-Results-on-May-4-2017-Conference-Call-to-Follow-04-27-2017 https://www.agenusbio.com/press/Agenus-to-Report-First-Quarter-2018-Financial-Results-on-May-7-2018-and-Host-Conference-Call-and-Webcast-05-03-2018 https://www.agenusbio.com/fr/press/Agenus-to-Report-First-Quarter-2018-Financial-Results-on-May-7-2018-and-Host-Conference-Call-and-Webcast-05-03-2018 https://www.agenusbio.com/es/press/Agenus-to-Report-First-Quarter-2018-Financial-Results-on-May-7-2018-and-Host-Conference-Call-and-Webcast-05-03-2018 https://www.agenusbio.com/press/Agenus-to-Report-First-Quarter-2019-Financial-Results-on-May-9-2019-and-Host-Conference-Call-and-Webcast-05-03-2019 https://www.agenusbio.com/fr/press/Agenus-to-Report-First-Quarter-2019-Financial-Results-on-May-9-2019-and-Host-Conference-Call-and-Webcast-05-03-2019 https://www.agenusbio.com/es/press/Agenus-to-Report-First-Quarter-2019-Financial-Results-on-May-9-2019-and-Host-Conference-Call-and-Webcast-05-03-2019 https://www.agenusbio.com/press/Agenus-to-Report-First-Quarter-2020-Financial-Results-on-May-7-2020-and-Host-Conference-Call-and-Webcast-04-28-2020 https://www.agenusbio.com/fr/press/Agenus-to-Report-First-Quarter-2020-Financial-Results-on-May-7-2020-and-Host-Conference-Call-and-Webcast-04-28-2020 https://www.agenusbio.com/es/press/Agenus-to-Report-First-Quarter-2020-Financial-Results-on-May-7-2020-and-Host-Conference-Call-and-Webcast-04-28-2020 https://www.agenusbio.com/press/Agenus-to-Report-Fourth-Quarter-and-Full-Year-2017-Financial-Results-on-March-15-2018-and-Host-Conference-Call-and-Webcast-03-07-2018 https://www.agenusbio.com/fr/press/Agenus-to-Report-Fourth-Quarter-and-Full-Year-2017-Financial-Results-on-March-15-2018-and-Host-Conference-Call-and-Webcast-03-07-2018 https://www.agenusbio.com/es/press/Agenus-to-Report-Fourth-Quarter-and-Full-Year-2017-Financial-Results-on-March-15-2018-and-Host-Conference-Call-and-Webcast-03-07-2018 https://www.agenusbio.com/press/Agenus-to-Report-Fourth-Quarter-and-Full-Year-2018-Financial-Results-on-March-14-2019-and-Host-Conference-Call-and-Webcast-03-08-2019 https://www.agenusbio.com/fr/press/Agenus-to-Report-Fourth-Quarter-and-Full-Year-2018-Financial-Results-on-March-14-2019-and-Host-Conference-Call-and-Webcast-03-08-2019 https://www.agenusbio.com/es/press/Agenus-to-Report-Fourth-Quarter-and-Full-Year-2018-Financial-Results-on-March-14-2019-and-Host-Conference-Call-and-Webcast-03-08-2019 https://www.agenusbio.com/press/Agenus-to-Report-Fourth-Quarter-and-Full-Year-2019-Financial-Results-on-March-12-2020-with-Conference-Call-and-Webcast-03-03-2020 https://www.agenusbio.com/fr/press/Agenus-to-Report-Fourth-Quarter-and-Full-Year-2019-Financial-Results-on-March-12-2020-with-Conference-Call-and-Webcast-03-03-2020 https://www.agenusbio.com/es/press/Agenus-to-Report-Fourth-Quarter-and-Full-Year-2019-Financial-Results-on-March-12-2020-with-Conference-Call-and-Webcast-03-03-2020 https://www.agenusbio.com/press/Agenus-to-Report-Fourth-Quarter-and-Year-End-2014-Financial-Results-on-February-26-2015-Conference-Call-to-Follow-02-20-2015 https://www.agenusbio.com/fr/press/Agenus-to-Report-Fourth-Quarter-and-Year-End-2014-Financial-Results-on-February-26-2015-Conference-Call-to-Follow-02-20-2015 https://www.agenusbio.com/es/press/Agenus-to-Report-Fourth-Quarter-and-Year-End-2014-Financial-Results-on-February-26-2015-Conference-Call-to-Follow-02-20-2015 https://www.agenusbio.com/press/Agenus-to-Report-Fourth-Quarter-and-Year-End-2015-Financial-Results-on-March-3-2016-Conference-Call-to-Follow-02-25-2016 https://www.agenusbio.com/fr/press/Agenus-to-Report-Fourth-Quarter-and-Year-End-2015-Financial-Results-on-March-3-2016-Conference-Call-to-Follow-02-25-2016 https://www.agenusbio.com/es/press/Agenus-to-Report-Fourth-Quarter-and-Year-End-2015-Financial-Results-on-March-3-2016-Conference-Call-to-Follow-02-25-2016 https://www.agenusbio.com/press/Agenus-to-Report-Fourth-Quarter-and-Year-End-2016-Financial-Results-on-March-9-2017-Conference-Call-to-Follow-03-02-2017 https://www.agenusbio.com/fr/press/Agenus-to-Report-Fourth-Quarter-and-Year-End-2016-Financial-Results-on-March-9-2017-Conference-Call-to-Follow-03-02-2017 https://www.agenusbio.com/es/press/Agenus-to-Report-Fourth-Quarter-and-Year-End-2016-Financial-Results-on-March-9-2017-Conference-Call-to-Follow-03-02-2017 https://www.agenusbio.com/press/Agenus-to-Report-Second-Quarter-2013-Financial-Results-on-July-25-2013-Conference-Call-to-Follow-07-18-2013 https://www.agenusbio.com/fr/press/Agenus-to-Report-Second-Quarter-2013-Financial-Results-on-July-25-2013-Conference-Call-to-Follow-07-18-2013 https://www.agenusbio.com/es/press/Agenus-to-Report-Second-Quarter-2013-Financial-Results-on-July-25-2013-Conference-Call-to-Follow-07-18-2013 https://www.agenusbio.com/press/Agenus-to-Report-Second-Quarter-2014-Financial-Results-on-July-24-2014-Conference-Call-to-Follow-07-17-2014 https://www.agenusbio.com/fr/press/Agenus-to-Report-Second-Quarter-2014-Financial-Results-on-July-24-2014-Conference-Call-to-Follow-07-17-2014 https://www.agenusbio.com/es/press/Agenus-to-Report-Second-Quarter-2014-Financial-Results-on-July-24-2014-Conference-Call-to-Follow-07-17-2014 https://www.agenusbio.com/press/Agenus-to-Report-Second-Quarter-2015-Financial-Results-on-July-23-2015-Conference-Call-to-Follow-07-16-2015 https://www.agenusbio.com/fr/press/Agenus-to-Report-Second-Quarter-2015-Financial-Results-on-July-23-2015-Conference-Call-to-Follow-07-16-2015 https://www.agenusbio.com/es/press/Agenus-to-Report-Second-Quarter-2015-Financial-Results-on-July-23-2015-Conference-Call-to-Follow-07-16-2015 https://www.agenusbio.com/press/Agenus-to-Report-Second-Quarter-2016-Financial-Results-on-July-28-2016-Conference-Call-to-Follow-07-21-2016 https://www.agenusbio.com/fr/press/Agenus-to-Report-Second-Quarter-2016-Financial-Results-on-July-28-2016-Conference-Call-to-Follow-07-21-2016 https://www.agenusbio.com/es/press/Agenus-to-Report-Second-Quarter-2016-Financial-Results-on-July-28-2016-Conference-Call-to-Follow-07-21-2016 https://www.agenusbio.com/press/Agenus-to-Report-Second-Quarter-2017-Financial-Results-on-August-3-2017-Conference-Call-to-Follow-07-27-2017 https://www.agenusbio.com/fr/press/Agenus-to-Report-Second-Quarter-2017-Financial-Results-on-August-3-2017-Conference-Call-to-Follow-07-27-2017 https://www.agenusbio.com/es/press/Agenus-to-Report-Second-Quarter-2017-Financial-Results-on-August-3-2017-Conference-Call-to-Follow-07-27-2017 https://www.agenusbio.com/press/Agenus-to-Report-Second-Quarter-2018-Financial-Results-on-August-9-2018-and-Host-Conference-Call-and-Webcast-08-02-2018 https://www.agenusbio.com/fr/press/Agenus-to-Report-Second-Quarter-2018-Financial-Results-on-August-9-2018-and-Host-Conference-Call-and-Webcast-08-02-2018 https://www.agenusbio.com/es/press/Agenus-to-Report-Second-Quarter-2018-Financial-Results-on-August-9-2018-and-Host-Conference-Call-and-Webcast-08-02-2018 https://www.agenusbio.com/press/Agenus-to-Report-Second-Quarter-2019-Financial-Results-on-August-8-2019-and-Host-Conference-Call-and-Webcast-08-06-2019 https://www.agenusbio.com/fr/press/Agenus-to-Report-Second-Quarter-2019-Financial-Results-on-August-8-2019-and-Host-Conference-Call-and-Webcast-08-06-2019 https://www.agenusbio.com/es/press/Agenus-to-Report-Second-Quarter-2019-Financial-Results-on-August-8-2019-and-Host-Conference-Call-and-Webcast-08-06-2019 https://www.agenusbio.com/press/Agenus-to-Report-Third-Quarter-2014-Financial-Results-on-October-31-2014-Conference-Call-to-Follow-10-27-2014 https://www.agenusbio.com/fr/press/Agenus-to-Report-Third-Quarter-2014-Financial-Results-on-October-31-2014-Conference-Call-to-Follow-10-27-2014 https://www.agenusbio.com/es/press/Agenus-to-Report-Third-Quarter-2014-Financial-Results-on-October-31-2014-Conference-Call-to-Follow-10-27-2014 https://www.agenusbio.com/press/Agenus-to-Report-Third-Quarter-2015-Financial-Results-on-October-27-2015-Conference-Call-to-Follow-10-20-2015 https://www.agenusbio.com/fr/press/Agenus-to-Report-Third-Quarter-2015-Financial-Results-on-October-27-2015-Conference-Call-to-Follow-10-20-2015 https://www.agenusbio.com/es/press/Agenus-to-Report-Third-Quarter-2015-Financial-Results-on-October-27-2015-Conference-Call-to-Follow-10-20-2015 https://www.agenusbio.com/press/Agenus-to-Report-Third-Quarter-2016-Financial-Results-on-October-27-2016-Conference-Call-to-Follow-10-20-2016 https://www.agenusbio.com/fr/press/Agenus-to-Report-Third-Quarter-2016-Financial-Results-on-October-27-2016-Conference-Call-to-Follow-10-20-2016 https://www.agenusbio.com/es/press/Agenus-to-Report-Third-Quarter-2016-Financial-Results-on-October-27-2016-Conference-Call-to-Follow-10-20-2016 https://www.agenusbio.com/press/Agenus-to-Report-Third-Quarter-2017-Financial-Results-on-November-7-2017-and-Host-Conference-Call-and-Webcast-10-26-2017 https://www.agenusbio.com/fr/press/Agenus-to-Report-Third-Quarter-2017-Financial-Results-on-November-7-2017-and-Host-Conference-Call-and-Webcast-10-26-2017 https://www.agenusbio.com/es/press/Agenus-to-Report-Third-Quarter-2017-Financial-Results-on-November-7-2017-and-Host-Conference-Call-and-Webcast-10-26-2017 https://www.agenusbio.com/press/Agenus-to-Report-Third-Quarter-2018-Financial-Results-on-November-6-2018-and-Host-Conference-Call-and-Webcast-10-31-2018 https://www.agenusbio.com/fr/press/Agenus-to-Report-Third-Quarter-2018-Financial-Results-on-November-6-2018-and-Host-Conference-Call-and-Webcast-10-31-2018 https://www.agenusbio.com/es/press/Agenus-to-Report-Third-Quarter-2018-Financial-Results-on-November-6-2018-and-Host-Conference-Call-and-Webcast-10-31-2018 https://www.agenusbio.com/press/Agenus-to-Report-Third-Quarter-2019-Financial-Results-on-November-4-2019-and-Host-Conference-Call-and-Webcast-10-31-2019 https://www.agenusbio.com/fr/press/Agenus-to-Report-Third-Quarter-2019-Financial-Results-on-November-4-2019-and-Host-Conference-Call-and-Webcast-10-31-2019 https://www.agenusbio.com/es/press/Agenus-to-Report-Third-Quarter-2019-Financial-Results-on-November-4-2019-and-Host-Conference-Call-and-Webcast-10-31-2019 https://www.agenusbio.com/press/Agenus-to-Report-Third-Quarter-Earnings-10-20-2020 https://www.agenusbio.com/fr/press/Agenus-to-Report-Third-Quarter-Earnings-10-20-2020 https://www.agenusbio.com/es/press/Agenus-to-Report-Third-Quarter-Earnings-10-20-2020 https://www.agenusbio.com/press/Agenus-to-Unveil-BOTBAL-Strategic-Advancements-Key-Milestones-and-Future-Outlook-in-Virtual-Stakeholder-Briefing-on-August-27-2025-f15dc https://www.agenusbio.com/fr/press/Agenus-to-Unveil-BOTBAL-Strategic-Advancements-Key-Milestones-and-Future-Outlook-in-Virtual-Stakeholder-Briefing-on-August-27-2025-f15dc https://www.agenusbio.com/es/press/Agenus-to-Unveil-BOTBAL-Strategic-Advancements-Key-Milestones-and-Future-Outlook-in-Virtual-Stakeholder-Briefing-on-August-27-2025-f15dc https://www.agenusbio.com/press/Agenus-to-Webcast-Annual-Meeting-of-Stockholders-06-20-2018 https://www.agenusbio.com/fr/press/Agenus-to-Webcast-Annual-Meeting-of-Stockholders-06-20-2018 https://www.agenusbio.com/es/press/Agenus-to-Webcast-Annual-Meeting-of-Stockholders-06-20-2018 https://www.agenusbio.com/press/Agenus-to-Webcast-Annual-Shareholders-Meeting-06-10-2013 https://www.agenusbio.com/fr/press/Agenus-to-Webcast-Annual-Shareholders-Meeting-06-10-2013 https://www.agenusbio.com/es/press/Agenus-to-Webcast-Annual-Shareholders-Meeting-06-10-2013 https://www.agenusbio.com/press/Agenus-to-present-safety-results-for-anti-CTLA-4-antibody-at-ASCO-2017-Annual-Meeting-05-22-2017 https://www.agenusbio.com/fr/press/Agenus-to-present-safety-results-for-anti-CTLA-4-antibody-at-ASCO-2017-Annual-Meeting-05-22-2017 https://www.agenusbio.com/es/press/Agenus-to-present-safety-results-for-anti-CTLA-4-antibody-at-ASCO-2017-Annual-Meeting-05-22-2017 https://www.agenusbio.com/press/An-Agenus-discovered-first-in-class-ILT4-antibody-MK-4830-enters-Phase-2-11-10-2020 https://www.agenusbio.com/fr/press/An-Agenus-discovered-first-in-class-ILT4-antibody-MK-4830-enters-Phase-2-11-10-2020 https://www.agenusbio.com/es/press/An-Agenus-discovered-first-in-class-ILT4-antibody-MK-4830-enters-Phase-2-11-10-2020 https://www.agenusbio.com/press/Andy-Hurley-Named-Agenus-Chief-Commercial-Officer-02-09-2021 https://www.agenusbio.com/fr/press/Andy-Hurley-Named-Agenus-Chief-Commercial-Officer-02-09-2021 https://www.agenusbio.com/es/press/Andy-Hurley-Named-Agenus-Chief-Commercial-Officer-02-09-2021 https://www.agenusbio.com/press/Balstilimab-Monotherapy-Data-Published-in-Gynecologic-Oncology-08-26-2021 https://www.agenusbio.com/fr/press/Balstilimab-Monotherapy-Data-Published-in-Gynecologic-Oncology-08-26-2021 https://www.agenusbio.com/es/press/Balstilimab-Monotherapy-Data-Published-in-Gynecologic-Oncology-08-26-2021 https://www.agenusbio.com/press/Balstilimab-Plus-Zalifrelimab-Data-Published-in-Journal-of-Clinical-Oncology-JCO-12-22-2021 https://www.agenusbio.com/fr/press/Balstilimab-Plus-Zalifrelimab-Data-Published-in-Journal-of-Clinical-Oncology-JCO-12-22-2021 https://www.agenusbio.com/es/press/Balstilimab-Plus-Zalifrelimab-Data-Published-in-Journal-of-Clinical-Oncology-JCO-12-22-2021 https://www.agenusbio.com/press/BotensilimabBalstilimab-Breakthrough-Data-Presented-at-ASCO-GI-Shows-Unprecedented-Tumor-Shrinkage-and-Robust-Biomarker-Response-in-Prevalent-Colorectal-Cancer-Population https://www.agenusbio.com/fr/press/BotensilimabBalstilimab-Breakthrough-Data-Presented-at-ASCO-GI-Shows-Unprecedented-Tumor-Shrinkage-and-Robust-Biomarker-Response-in-Prevalent-Colorectal-Cancer-Population https://www.agenusbio.com/es/press/BotensilimabBalstilimab-Breakthrough-Data-Presented-at-ASCO-GI-Shows-Unprecedented-Tumor-Shrinkage-and-Robust-Biomarker-Response-in-Prevalent-Colorectal-Cancer-Population https://www.agenusbio.com/press/BotensilimabBalstilimab-Clinical-Activity-in-Refractory-Sarcomas-to-be-Presented-in-Oral-Session-at-ESMO-2024 https://www.agenusbio.com/fr/press/BotensilimabBalstilimab-Clinical-Activity-in-Refractory-Sarcomas-to-be-Presented-in-Oral-Session-at-ESMO-2024 https://www.agenusbio.com/es/press/BotensilimabBalstilimab-Clinical-Activity-in-Refractory-Sarcomas-to-be-Presented-in-Oral-Session-at-ESMO-2024 https://www.agenusbio.com/press/BotensilimabBalstilimab-Clinical-Responses-in-Refractory-Sarcomas-Presented-at-ESMO-2024 https://www.agenusbio.com/fr/press/BotensilimabBalstilimab-Clinical-Responses-in-Refractory-Sarcomas-Presented-at-ESMO-2024 https://www.agenusbio.com/es/press/BotensilimabBalstilimab-Clinical-Responses-in-Refractory-Sarcomas-Presented-at-ESMO-2024 https://www.agenusbio.com/press/BotensilimabBalstilimab-Data-in-MSS-CRC-Selected-for-the-American-Society-of-Clinical-Oncology-2024-Annual-Meeting https://www.agenusbio.com/fr/press/BotensilimabBalstilimab-Data-in-MSS-CRC-Selected-for-the-American-Society-of-Clinical-Oncology-2024-Annual-Meeting https://www.agenusbio.com/es/press/BotensilimabBalstilimab-Data-in-MSS-CRC-Selected-for-the-American-Society-of-Clinical-Oncology-2024-Annual-Meeting https://www.agenusbio.com/press/BotensilimabBalstilimab-Data-in-Neoadjuvant-Colorectal-Cancer-Selected-for-ASCO-GI-2024 https://www.agenusbio.com/fr/press/BotensilimabBalstilimab-Data-in-Neoadjuvant-Colorectal-Cancer-Selected-for-ASCO-GI-2024 https://www.agenusbio.com/es/press/BotensilimabBalstilimab-Data-in-Neoadjuvant-Colorectal-Cancer-Selected-for-ASCO-GI-2024 https://www.agenusbio.com/press/Breakthrough-Data-on-BotensilimabBalstilimab-in-MSS-CRC-Presented-at-the-2024-ASCO-Annual-Meeting https://www.agenusbio.com/fr/press/Breakthrough-Data-on-BotensilimabBalstilimab-in-MSS-CRC-Presented-at-the-2024-ASCO-Annual-Meeting https://www.agenusbio.com/es/press/Breakthrough-Data-on-BotensilimabBalstilimab-in-MSS-CRC-Presented-at-the-2024-ASCO-Annual-Meeting https://www.agenusbio.com/press/Bruno-Lucidi-Appointed-Chief-Executive-Officer-of-AgenTus-Therapeutics-The-Cell-Therapy-Subsidiary-of-Agenus-10-23-2017 https://www.agenusbio.com/fr/press/Bruno-Lucidi-Appointed-Chief-Executive-Officer-of-AgenTus-Therapeutics-The-Cell-Therapy-Subsidiary-of-Agenus-10-23-2017 https://www.agenusbio.com/es/press/Bruno-Lucidi-Appointed-Chief-Executive-Officer-of-AgenTus-Therapeutics-The-Cell-Therapy-Subsidiary-of-Agenus-10-23-2017 https://www.agenusbio.com/press/CORRECTING-and-REPLACING-Agenus-BOTBAL-Selected-for-Two-Presentations-at-Upcoming-AACR-IO-Annual-Meeting https://www.agenusbio.com/fr/press/CORRECTING-and-REPLACING-Agenus-BOTBAL-Selected-for-Two-Presentations-at-Upcoming-AACR-IO-Annual-Meeting https://www.agenusbio.com/es/press/CORRECTING-and-REPLACING-Agenus-BOTBAL-Selected-for-Two-Presentations-at-Upcoming-AACR-IO-Annual-Meeting https://www.agenusbio.com/press/Cancer-Therapy-Evaluation-Program-Announces-Availability-of-Botensilimab-for-Clinical-Studies https://www.agenusbio.com/fr/press/Cancer-Therapy-Evaluation-Program-Announces-Availability-of-Botensilimab-for-Clinical-Studies https://www.agenusbio.com/es/press/Cancer-Therapy-Evaluation-Program-Announces-Availability-of-Botensilimab-for-Clinical-Studies https://www.agenusbio.com/press/Clinical-Activity-of-AGEN1181-Demonstrated-Across-Nine-Treatment-Resistant-Cancers-at-SITC-11-12-2021 https://www.agenusbio.com/fr/press/Clinical-Activity-of-AGEN1181-Demonstrated-Across-Nine-Treatment-Resistant-Cancers-at-SITC-11-12-2021 https://www.agenusbio.com/es/press/Clinical-Activity-of-AGEN1181-Demonstrated-Across-Nine-Treatment-Resistant-Cancers-at-SITC-11-12-2021 https://www.agenusbio.com/press/Combination-of-Balstilimab-Plus-Zalifrelimab-Doubles-Responses-in-2L-Cervical-Cancer-in-Data-to-Be-Presented-at-ESMO-09-16-2021 https://www.agenusbio.com/fr/press/Combination-of-Balstilimab-Plus-Zalifrelimab-Doubles-Responses-in-2L-Cervical-Cancer-in-Data-to-Be-Presented-at-ESMO-09-16-2021 https://www.agenusbio.com/es/press/Combination-of-Balstilimab-Plus-Zalifrelimab-Doubles-Responses-in-2L-Cervical-Cancer-in-Data-to-Be-Presented-at-ESMO-09-16-2021 https://www.agenusbio.com/press/Completion-of-Balstilimab-BLA-Filing-Extended-To-1H2021-12-03-2020 https://www.agenusbio.com/fr/press/Completion-of-Balstilimab-BLA-Filing-Extended-To-1H2021-12-03-2020 https://www.agenusbio.com/es/press/Completion-of-Balstilimab-BLA-Filing-Extended-To-1H2021-12-03-2020 https://www.agenusbio.com/press/ESMO-2023-Agenus-BotensilimabBalstilimab-Combination-Delivers-Durable-Responses-across-Multiple-Sarcoma-Subtypes https://www.agenusbio.com/fr/press/ESMO-2023-Agenus-BotensilimabBalstilimab-Combination-Delivers-Durable-Responses-across-Multiple-Sarcoma-Subtypes https://www.agenusbio.com/es/press/ESMO-2023-Agenus-BotensilimabBalstilimab-Combination-Delivers-Durable-Responses-across-Multiple-Sarcoma-Subtypes https://www.agenusbio.com/press/ESMO-GI-Data-Agenus-BotensilimabBalstilimab-Combination-Achieves-Unprecedented-Survival-in-Advanced-Colorectal-Cancer-06-30-2023 https://www.agenusbio.com/fr/press/ESMO-GI-Data-Agenus-BotensilimabBalstilimab-Combination-Achieves-Unprecedented-Survival-in-Advanced-Colorectal-Cancer-06-30-2023 https://www.agenusbio.com/es/press/ESMO-GI-Data-Agenus-BotensilimabBalstilimab-Combination-Achieves-Unprecedented-Survival-in-Advanced-Colorectal-Cancer-06-30-2023 https://www.agenusbio.com/press/FDA-Approves-GSKs-Shingles-Vaccine-with-Agenus-QS-21-Stimulon-Adjuvant-10-20-2017 https://www.agenusbio.com/fr/press/FDA-Approves-GSKs-Shingles-Vaccine-with-Agenus-QS-21-Stimulon-Adjuvant-10-20-2017 https://www.agenusbio.com/es/press/FDA-Approves-GSKs-Shingles-Vaccine-with-Agenus-QS-21-Stimulon-Adjuvant-10-20-2017 https://www.agenusbio.com/press/FDA-Clears-AgenTus-IND-for-Allogeneic-iNKT-Cell-Therapy-05-13-2020 https://www.agenusbio.com/fr/press/FDA-Clears-AgenTus-IND-for-Allogeneic-iNKT-Cell-Therapy-05-13-2020 https://www.agenusbio.com/es/press/FDA-Clears-AgenTus-IND-for-Allogeneic-iNKT-Cell-Therapy-05-13-2020 https://www.agenusbio.com/press/FDA-Clears-IND-for-iNKT-Cells-to-Treat-COVID-19-Patients-06-02-2020 https://www.agenusbio.com/fr/press/FDA-Clears-IND-for-iNKT-Cells-to-Treat-COVID-19-Patients-06-02-2020 https://www.agenusbio.com/es/press/FDA-Clears-IND-for-iNKT-Cells-to-Treat-COVID-19-Patients-06-02-2020 https://www.agenusbio.com/press/FDA-Grants-Agenus-Type-B-End-of-Phase-2-Meeting-to-Discuss-BOTBAL-Therapy-for-Relapsed-or-Refractory-Metastatic-Colorectal-Cancer https://www.agenusbio.com/fr/press/FDA-Grants-Agenus-Type-B-End-of-Phase-2-Meeting-to-Discuss-BOTBAL-Therapy-for-Relapsed-or-Refractory-Metastatic-Colorectal-Cancer https://www.agenusbio.com/es/press/FDA-Grants-Agenus-Type-B-End-of-Phase-2-Meeting-to-Discuss-BOTBAL-Therapy-for-Relapsed-or-Refractory-Metastatic-Colorectal-Cancer https://www.agenusbio.com/press/First-QS-21-Royalty-Payment-Due-to-Agenus-is-Triggered-03-10-2020 https://www.agenusbio.com/fr/press/First-QS-21-Royalty-Payment-Due-to-Agenus-is-Triggered-03-10-2020 https://www.agenusbio.com/es/press/First-QS-21-Royalty-Payment-Due-to-Agenus-is-Triggered-03-10-2020 https://www.agenusbio.com/press/First-Vaccine-Candidate-for-Malaria-is-Accepted-for-EU-Regulatory-Review-07-24-2014 https://www.agenusbio.com/fr/press/First-Vaccine-Candidate-for-Malaria-is-Accepted-for-EU-Regulatory-Review-07-24-2014 https://www.agenusbio.com/es/press/First-Vaccine-Candidate-for-Malaria-is-Accepted-for-EU-Regulatory-Review-07-24-2014 https://www.agenusbio.com/press/Four-Agenus-Abstracts-Accepted-for-Presentation-at-the-American-Association-for-Cancer-Research-AACR-2017-Annual-Meeting-03-07-2017 https://www.agenusbio.com/fr/press/Four-Agenus-Abstracts-Accepted-for-Presentation-at-the-American-Association-for-Cancer-Research-AACR-2017-Annual-Meeting-03-07-2017 https://www.agenusbio.com/es/press/Four-Agenus-Abstracts-Accepted-for-Presentation-at-the-American-Association-for-Cancer-Research-AACR-2017-Annual-Meeting-03-07-2017 https://www.agenusbio.com/press/France-Expands-National-AAC-Access-for-Agenus-Botensilimab--Balstilimab-for-Ovarian-Cancer-and-Soft-Tissue-Sarcomas-f91ff https://www.agenusbio.com/fr/press/France-Expands-National-AAC-Access-for-Agenus-Botensilimab--Balstilimab-for-Ovarian-Cancer-and-Soft-Tissue-Sarcomas-f91ff https://www.agenusbio.com/es/press/France-Expands-National-AAC-Access-for-Agenus-Botensilimab--Balstilimab-for-Ovarian-Cancer-and-Soft-Tissue-Sarcomas-f91ff https://www.agenusbio.com/press/France-Grants-Reimbursed-Compassionate-Access-AAC-for-Agenus-BOTBAL-in-Refractory-MSS-Metastatic-Colorectal-Cancer-6263f https://www.agenusbio.com/fr/press/France-Grants-Reimbursed-Compassionate-Access-AAC-for-Agenus-BOTBAL-in-Refractory-MSS-Metastatic-Colorectal-Cancer-6263f https://www.agenusbio.com/es/press/France-Grants-Reimbursed-Compassionate-Access-AAC-for-Agenus-BOTBAL-in-Refractory-MSS-Metastatic-Colorectal-Cancer-6263f https://www.agenusbio.com/press/GSKS-MAGE-A3-Cancer-Immunotherapeutic-Phase-3-Study-in-Melanoma-Misses-First-Co-Primary-Endpoint-09-05-2013 https://www.agenusbio.com/fr/press/GSKS-MAGE-A3-Cancer-Immunotherapeutic-Phase-3-Study-in-Melanoma-Misses-First-Co-Primary-Endpoint-09-05-2013 https://www.agenusbio.com/es/press/GSKS-MAGE-A3-Cancer-Immunotherapeutic-Phase-3-Study-in-Melanoma-Misses-First-Co-Primary-Endpoint-09-05-2013 https://www.agenusbio.com/press/GSKs-Malaria-Vaccine-Containing-Agenus-QS-21-Stimulon-Receives-Positive-Opinion-from-European-Regulators-for-Prevention-of-Malaria-in-Young-Children-in-Sub-Saharan-Africa-07-24-2015 https://www.agenusbio.com/fr/press/GSKs-Malaria-Vaccine-Containing-Agenus-QS-21-Stimulon-Receives-Positive-Opinion-from-European-Regulators-for-Prevention-of-Malaria-in-Young-Children-in-Sub-Saharan-Africa-07-24-2015 https://www.agenusbio.com/es/press/GSKs-Malaria-Vaccine-Containing-Agenus-QS-21-Stimulon-Receives-Positive-Opinion-from-European-Regulators-for-Prevention-of-Malaria-in-Young-Children-in-Sub-Saharan-Africa-07-24-2015 https://www.agenusbio.com/press/GSKs-Malaria-Vaccine-Phase-3-Study-Containing-Agenus-QS-21-Published-in-The-Lancet-04-24-2015 https://www.agenusbio.com/fr/press/GSKs-Malaria-Vaccine-Phase-3-Study-Containing-Agenus-QS-21-Published-in-The-Lancet-04-24-2015 https://www.agenusbio.com/es/press/GSKs-Malaria-Vaccine-Phase-3-Study-Containing-Agenus-QS-21-Published-in-The-Lancet-04-24-2015 https://www.agenusbio.com/press/GSKs-RSV-vaccine-candidate-for-older-adults-containing-Agenus-QS-21-STIMULON-as-part-of-GSKs-AS01-adjuvant-reports-positive-pivotal-data-supporting-initiation-of-global-regulatory-submissions-06-10-2022 https://www.agenusbio.com/fr/press/GSKs-RSV-vaccine-candidate-for-older-adults-containing-Agenus-QS-21-STIMULON-as-part-of-GSKs-AS01-adjuvant-reports-positive-pivotal-data-supporting-initiation-of-global-regulatory-submissions-06-10-2022 https://www.agenusbio.com/es/press/GSKs-RSV-vaccine-candidate-for-older-adults-containing-Agenus-QS-21-STIMULON-as-part-of-GSKs-AS01-adjuvant-reports-positive-pivotal-data-supporting-initiation-of-global-regulatory-submissions-06-10-2022 https://www.agenusbio.com/press/GSKs-Shingrix-Containing-Agenus-QS-21-Stimulon-Adjuvant-Receives-Marketing-Authorization-from-Health-Canada-10-13-2017 https://www.agenusbio.com/fr/press/GSKs-Shingrix-Containing-Agenus-QS-21-Stimulon-Adjuvant-Receives-Marketing-Authorization-from-Health-Canada-10-13-2017 https://www.agenusbio.com/es/press/GSKs-Shingrix-Containing-Agenus-QS-21-Stimulon-Adjuvant-Receives-Marketing-Authorization-from-Health-Canada-10-13-2017 https://www.agenusbio.com/press/GSKs-Shingrix-containing-Agenus-QS-21-Stimulon-adjuvant-receives-Unanimous-FDA-Advisory-Committee-recommendation-for-approval-09-13-2017 https://www.agenusbio.com/fr/press/GSKs-Shingrix-containing-Agenus-QS-21-Stimulon-adjuvant-receives-Unanimous-FDA-Advisory-Committee-recommendation-for-approval-09-13-2017 https://www.agenusbio.com/es/press/GSKs-Shingrix-containing-Agenus-QS-21-Stimulon-adjuvant-receives-Unanimous-FDA-Advisory-Committee-recommendation-for-approval-09-13-2017 https://www.agenusbio.com/press/GSKs-Vaccine-Candidate-Containing-Agenus-QS-21-Stimulon-Reduces-Malaria-Infection-in-Phase-3-Trials-of-Over-15000-Children-10-07-2013 https://www.agenusbio.com/fr/press/GSKs-Vaccine-Candidate-Containing-Agenus-QS-21-Stimulon-Reduces-Malaria-Infection-in-Phase-3-Trials-of-Over-15000-Children-10-07-2013 https://www.agenusbio.com/es/press/GSKs-Vaccine-Candidate-Containing-Agenus-QS-21-Stimulon-Reduces-Malaria-Infection-in-Phase-3-Trials-of-Over-15000-Children-10-07-2013 https://www.agenusbio.com/press/GSKs-candidate-Shingles-Vaccine-Containing-Agenus-QS-21-Stimulon-Demonstrates-90-Efficacy-against-Shingles-and-89-Efficacy-against-Post-Herpetic-Neuralgia-in-Adults-aged-70-Years-and-Older-10-27-2015 https://www.agenusbio.com/fr/press/GSKs-candidate-Shingles-Vaccine-Containing-Agenus-QS-21-Stimulon-Demonstrates-90-Efficacy-against-Shingles-and-89-Efficacy-against-Post-Herpetic-Neuralgia-in-Adults-aged-70-Years-and-Older-10-27-2015 https://www.agenusbio.com/es/press/GSKs-candidate-Shingles-Vaccine-Containing-Agenus-QS-21-Stimulon-Demonstrates-90-Efficacy-against-Shingles-and-89-Efficacy-against-Post-Herpetic-Neuralgia-in-Adults-aged-70-Years-and-Older-10-27-2015 https://www.agenusbio.com/press/Gilead-And-Agenus-Enter-into-Collaboration-to-Develop-Immuno-Oncology-Therapies-12-20-2018 https://www.agenusbio.com/fr/press/Gilead-And-Agenus-Enter-into-Collaboration-to-Develop-Immuno-Oncology-Therapies-12-20-2018 https://www.agenusbio.com/es/press/Gilead-And-Agenus-Enter-into-Collaboration-to-Develop-Immuno-Oncology-Therapies-12-20-2018 https://www.agenusbio.com/press/Incyte-and-Agenus-Announce-Global-Alliance-to-Develop-Novel-Immuno-Oncology-Antibodies-01-09-2015 https://www.agenusbio.com/fr/press/Incyte-and-Agenus-Announce-Global-Alliance-to-Develop-Novel-Immuno-Oncology-Antibodies-01-09-2015 https://www.agenusbio.com/es/press/Incyte-and-Agenus-Announce-Global-Alliance-to-Develop-Novel-Immuno-Oncology-Antibodies-01-09-2015 https://www.agenusbio.com/press/Ligand-and-Agenus-Enter-Into-100-Million-Royalty-Financing-Agreement-2024-1UFqFumAqe https://www.agenusbio.com/fr/press/Ligand-and-Agenus-Enter-Into-100-Million-Royalty-Financing-Agreement-2024-1UFqFumAqe https://www.agenusbio.com/es/press/Ligand-and-Agenus-Enter-Into-100-Million-Royalty-Financing-Agreement-2024-1UFqFumAqe https://www.agenusbio.com/press/Merck-Extends-Immuno-Oncology-Collaboration-with-Agenus-06-03-2015 https://www.agenusbio.com/fr/press/Merck-Extends-Immuno-Oncology-Collaboration-with-Agenus-06-03-2015 https://www.agenusbio.com/es/press/Merck-Extends-Immuno-Oncology-Collaboration-with-Agenus-06-03-2015 https://www.agenusbio.com/press/MiNK-Therapeutics-Announces-Confidential-Submission-of-Draft-Registration-Statement-for-Proposed-Initial-Public-Offering-07-28-2021 https://www.agenusbio.com/fr/press/MiNK-Therapeutics-Announces-Confidential-Submission-of-Draft-Registration-Statement-for-Proposed-Initial-Public-Offering-07-28-2021 https://www.agenusbio.com/es/press/MiNK-Therapeutics-Announces-Confidential-Submission-of-Draft-Registration-Statement-for-Proposed-Initial-Public-Offering-07-28-2021 https://www.agenusbio.com/press/NEJM-Publishes-Study-Showing-GSKs-Shingles-Vaccine-Containing-Agenus-QS-21-Stimulon-Adjuvant-Provides-over-97-Protection-in-People-Over-the-Age-of-50-04-28-2015 https://www.agenusbio.com/fr/press/NEJM-Publishes-Study-Showing-GSKs-Shingles-Vaccine-Containing-Agenus-QS-21-Stimulon-Adjuvant-Provides-over-97-Protection-in-People-Over-the-Age-of-50-04-28-2015 https://www.agenusbio.com/es/press/NEJM-Publishes-Study-Showing-GSKs-Shingles-Vaccine-Containing-Agenus-QS-21-Stimulon-Adjuvant-Provides-over-97-Protection-in-People-Over-the-Age-of-50-04-28-2015 https://www.agenusbio.com/press/Nature-Medicine-Reports-Agenus-Novel-Immunotherapy-Demonstrates-Clinical-Activity-Against-a-Deadly-Form-of-Colorectal-Cancer-on-the-Rise-in-Americans-Under-50 https://www.agenusbio.com/fr/press/Nature-Medicine-Reports-Agenus-Novel-Immunotherapy-Demonstrates-Clinical-Activity-Against-a-Deadly-Form-of-Colorectal-Cancer-on-the-Rise-in-Americans-Under-50 https://www.agenusbio.com/es/press/Nature-Medicine-Reports-Agenus-Novel-Immunotherapy-Demonstrates-Clinical-Activity-Against-a-Deadly-Form-of-Colorectal-Cancer-on-the-Rise-in-Americans-Under-50 https://www.agenusbio.com/press/New-Agenus-Subsidiary-SaponiQx-Builds-Innovative-Adjuvant-Platform-and-Forms-Collaboration-with-Ginkgo-Bioworks-09-10-2021 https://www.agenusbio.com/fr/press/New-Agenus-Subsidiary-SaponiQx-Builds-Innovative-Adjuvant-Platform-and-Forms-Collaboration-with-Ginkgo-Bioworks-09-10-2021 https://www.agenusbio.com/es/press/New-Agenus-Subsidiary-SaponiQx-Builds-Innovative-Adjuvant-Platform-and-Forms-Collaboration-with-Ginkgo-Bioworks-09-10-2021 https://www.agenusbio.com/press/New-Clinical-Responses-for-AGEN1181-Presented-at-AACR-04-10-2021 https://www.agenusbio.com/fr/press/New-Clinical-Responses-for-AGEN1181-Presented-at-AACR-04-10-2021 https://www.agenusbio.com/es/press/New-Clinical-Responses-for-AGEN1181-Presented-at-AACR-04-10-2021 https://www.agenusbio.com/press/Paul-Clark-Joins-Agenus-Board-of-Directors-08-31-2020 https://www.agenusbio.com/fr/press/Paul-Clark-Joins-Agenus-Board-of-Directors-08-31-2020 https://www.agenusbio.com/es/press/Paul-Clark-Joins-Agenus-Board-of-Directors-08-31-2020 https://www.agenusbio.com/press/Phase-12-Clinical-Trial-of-Agenus-anti-PD-1-Antibody-Begins-04-20-2017 https://www.agenusbio.com/fr/press/Phase-12-Clinical-Trial-of-Agenus-anti-PD-1-Antibody-Begins-04-20-2017 https://www.agenusbio.com/es/press/Phase-12-Clinical-Trial-of-Agenus-anti-PD-1-Antibody-Begins-04-20-2017 https://www.agenusbio.com/press/Positive-Outcome-of-Phase-3-Study-of-GSK-Shingles-Vaccine-Containing-Agenus-Adjuvant-12-18-2014 https://www.agenusbio.com/fr/press/Positive-Outcome-of-Phase-3-Study-of-GSK-Shingles-Vaccine-Containing-Agenus-Adjuvant-12-18-2014 https://www.agenusbio.com/es/press/Positive-Outcome-of-Phase-3-Study-of-GSK-Shingles-Vaccine-Containing-Agenus-Adjuvant-12-18-2014 https://www.agenusbio.com/press/Positive-Phase-2-Results-from-Agenus-Brain-Cancer-Vaccine-Published-in-Neuro-Oncology-12-16-2013 https://www.agenusbio.com/fr/press/Positive-Phase-2-Results-from-Agenus-Brain-Cancer-Vaccine-Published-in-Neuro-Oncology-12-16-2013 https://www.agenusbio.com/es/press/Positive-Phase-2-Results-from-Agenus-Brain-Cancer-Vaccine-Published-in-Neuro-Oncology-12-16-2013 https://www.agenusbio.com/press/Renowned-GI-Oncology-Leader-Dr--Richard-Goldberg-Joins-Agenus-as-Chief-Development-Officer https://www.agenusbio.com/fr/press/Renowned-GI-Oncology-Leader-Dr--Richard-Goldberg-Joins-Agenus-as-Chief-Development-Officer https://www.agenusbio.com/es/press/Renowned-GI-Oncology-Leader-Dr--Richard-Goldberg-Joins-Agenus-as-Chief-Development-Officer https://www.agenusbio.com/press/Shingrix-with-QS-21-Stimulon-Receives-Positive-Recommendation-from-CDCs-Advisory-Committee-on-Immunization-Practices-as-Preferred-Vaccine-for-Prevention-of-Shingles-10-25-2017 https://www.agenusbio.com/fr/press/Shingrix-with-QS-21-Stimulon-Receives-Positive-Recommendation-from-CDCs-Advisory-Committee-on-Immunization-Practices-as-Preferred-Vaccine-for-Prevention-of-Shingles-10-25-2017 https://www.agenusbio.com/es/press/Shingrix-with-QS-21-Stimulon-Receives-Positive-Recommendation-from-CDCs-Advisory-Committee-on-Immunization-Practices-as-Preferred-Vaccine-for-Prevention-of-Shingles-10-25-2017 https://www.agenusbio.com/press/Significant-Tumor-Reductions-in-Neoadjuvant-MSS-Colon-Cancer-Patients-Treated-with-BotensilimabBalstilimab-Presented-at-ESMO-GI-Conference https://www.agenusbio.com/fr/press/Significant-Tumor-Reductions-in-Neoadjuvant-MSS-Colon-Cancer-Patients-Treated-with-BotensilimabBalstilimab-Presented-at-ESMO-GI-Conference https://www.agenusbio.com/es/press/Significant-Tumor-Reductions-in-Neoadjuvant-MSS-Colon-Cancer-Patients-Treated-with-BotensilimabBalstilimab-Presented-at-ESMO-GI-Conference https://www.agenusbio.com/press/Susan-Hirsch-Joins-Agenus-Board-of-Directors-10-13-2020 https://www.agenusbio.com/fr/press/Susan-Hirsch-Joins-Agenus-Board-of-Directors-10-13-2020 https://www.agenusbio.com/es/press/Susan-Hirsch-Joins-Agenus-Board-of-Directors-10-13-2020 https://www.agenusbio.com/press/Targovax-ASA-and-Agenus-announce-collaboration-on-mutant-KRAS-cancer-vaccine-adjuvanted-with-QS-21-STIMULON-03-07-2022 https://www.agenusbio.com/fr/press/Targovax-ASA-and-Agenus-announce-collaboration-on-mutant-KRAS-cancer-vaccine-adjuvanted-with-QS-21-STIMULON-03-07-2022 https://www.agenusbio.com/es/press/Targovax-ASA-and-Agenus-announce-collaboration-on-mutant-KRAS-cancer-vaccine-adjuvanted-with-QS-21-STIMULON-03-07-2022 https://www.agenusbio.com/press/Three-Agenus-Abstracts-Accepted-for-Presentation-at-the-American-Association-for-Cancer-Research-AACR-2018-Annual-Meeting-04-11-2018 https://www.agenusbio.com/fr/press/Three-Agenus-Abstracts-Accepted-for-Presentation-at-the-American-Association-for-Cancer-Research-AACR-2018-Annual-Meeting-04-11-2018 https://www.agenusbio.com/es/press/Three-Agenus-Abstracts-Accepted-for-Presentation-at-the-American-Association-for-Cancer-Research-AACR-2018-Annual-Meeting-04-11-2018 https://www.agenusbio.com/press/Update-Agenus-Aug-27-Stakeholder-WebcastTransformative-IO-Updates-BOTBAL-Data-BATTMAN-Preview-Zydus-Partnership-Momentum-and-MiNK-Spotlight-572e4 https://www.agenusbio.com/fr/press/Update-Agenus-Aug-27-Stakeholder-WebcastTransformative-IO-Updates-BOTBAL-Data-BATTMAN-Preview-Zydus-Partnership-Momentum-and-MiNK-Spotlight-572e4 https://www.agenusbio.com/es/press/Update-Agenus-Aug-27-Stakeholder-WebcastTransformative-IO-Updates-BOTBAL-Data-BATTMAN-Preview-Zydus-Partnership-Momentum-and-MiNK-Spotlight-572e4 https://www.agenusbio.com/press/Update-On-GSKS-MAGE-A3-Cancer-Immunotherapeutic-Phase-3-Study-in-Non-Small-Cell-Lung-Cancer-04-02-2014 https://www.agenusbio.com/fr/press/Update-On-GSKS-MAGE-A3-Cancer-Immunotherapeutic-Phase-3-Study-in-Non-Small-Cell-Lung-Cancer-04-02-2014 https://www.agenusbio.com/es/press/Update-On-GSKS-MAGE-A3-Cancer-Immunotherapeutic-Phase-3-Study-in-Non-Small-Cell-Lung-Cancer-04-02-2014 https://www.agenusbio.com/press/Updated-Phase-2-Data-of-Prophage-In-Newly-Diagnosed-GBM-Presented-at-ASCO-Show-Improvement-in-Median-Progression-Free-Survival-and-Overall-Survival-Independently-of-Prognostic-Markers-Compared-with-Historical-Expectations-06-01-2015 https://www.agenusbio.com/fr/press/Updated-Phase-2-Data-of-Prophage-In-Newly-Diagnosed-GBM-Presented-at-ASCO-Show-Improvement-in-Median-Progression-Free-Survival-and-Overall-Survival-Independently-of-Prognostic-Markers-Compared-with-Historical-Expectations-06-01-2015 https://www.agenusbio.com/es/press/Updated-Phase-2-Data-of-Prophage-In-Newly-Diagnosed-GBM-Presented-at-ASCO-Show-Improvement-in-Median-Progression-Free-Survival-and-Overall-Survival-Independently-of-Prognostic-Markers-Compared-with-Historical-Expectations-06-01-2015 https://www.agenusbio.com/press/VBI-Vaccines-and-Agenus-Announce-Collaboration-to-Evaluate-VBI-1901-in-Combination-with-Anti-PD-1-Balstilimab-in-a-Phase-2-Study-in-Primary-Glioblastoma-Patients-10-12-2022 https://www.agenusbio.com/fr/press/VBI-Vaccines-and-Agenus-Announce-Collaboration-to-Evaluate-VBI-1901-in-Combination-with-Anti-PD-1-Balstilimab-in-a-Phase-2-Study-in-Primary-Glioblastoma-Patients-10-12-2022 https://www.agenusbio.com/es/press/VBI-Vaccines-and-Agenus-Announce-Collaboration-to-Evaluate-VBI-1901-in-Combination-with-Anti-PD-1-Balstilimab-in-a-Phase-2-Study-in-Primary-Glioblastoma-Patients-10-12-2022 https://www.agenusbio.com/press/agenus-announces-data-from-phase-ii-study-of-bot-bal-in-combination-with-agent-797-in-pd-1-refractory-gastroesophageal-cancer-to-be-presented-at-aacr-2026 https://www.agenusbio.com/press/agenus-announces-first-patient-enrolled-in-global-phase-3-battman-trial-of-bot-bal-immunotherapy-combination-in-mss-or-pmmr-metastatic-colorectal-cancer https://www.agenusbio.com/press/agenus-announces-upcoming-aacr-2026-presentation-evaluating-botensilimab-plus-balstilimab-in-first-line-mss-metastatic-colorectal-cancer https://www.agenusbio.com/press/agenus-names-bap-pharma-as-exclusive-global-partner-for-bot-bal-access-programs https://www.agenusbio.com/press/agenus-presents-biomarker-data-demonstrating-survival-stratification-in-mss-mcrc-and-other-immunologically-cold-tumors-treated-with-bot-bal https://www.agenusbio.com/press/agenus-reports-2025-results-bot-bal-advances-to-phase-3-and-early-access-programs-expand-globally-with-initial-revenues-recognized https://www.agenusbio.com/press/agenus-reports-phase-ii-data-demonstrating-immune-reprogramming-and-durable-survival-with-botensilimab-balstilimab-and-agent-797-in-pd-1-refractory-gastroesophageal-cancer https://www.agenusbio.com/press/agenus-reports-q3-2025-results-showcasing-clinical-and-regulatory-advances https://www.agenusbio.com/fr/press/agenus-reports-q3-2025-results-showcasing-clinical-and-regulatory-advances https://www.agenusbio.com/es/press/agenus-reports-q3-2025-results-showcasing-clinical-and-regulatory-advances https://www.agenusbio.com/press/agenus-to-host-march-2026-stakeholder-webcast-harnessing-the-immune-system-to-advance-bot-bal-across-tumor-types-and-expand-patient-access https://www.agenusbio.com/press/agenus-to-present-first-phase-2-botensilimab-data-in-advanced-cutaneous-melanoma-at-asco-2026 https://www.agenusbio.com/press/agenus-to-present-new-data-at-aacr-io-exploring-systemic-and-tumor-inflammation-biomarkers-with-bot-bal-in-immunologically-cold-tumors https://www.agenusbio.com/press/agenus-to-provide-fourth-quarter-and-year-end-2025-financial-report-and-corporate-update https://www.agenusbio.com/press/agenus-triggers-first-20m-contingent-payment-under-zydus-life-sciences-collaboration-to-support-bot-bal-manufacturing-needs